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ABSTRACT OF THE DISSERTATION
Increasing pH in cancer: enabling a new therapeutic paradigm using novel carbonate
nanoparticles
by
Avik Som
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2018
Professor Samuel Achilefu, Chair
Enormous progress has been made to treat cancer, and yet the mortality rate of cancer remains
unacceptably high. High clinical resistance to molecularly targeted therapeutics has pushed interest again
towards inhibiting universal biochemical hallmarks of cancer. Recent evidence suggests that malignant
tumors acidify the local extracellular environment to activate proteases for degrading the tumor matrix,
which facilitates metastasis, and explains why more aggressive tumors are more acidic. Current therapies
have only focused on using the low pH for enhancing drug release in tumors, thereby still relying on the
traditional paradigm of intracellular inhibition of pathways, a method that continues to have mixed
results.
In this dissertation we explore the development of a novel platform that can be made to monitor
and modify the critical tumor extracellular environment. The platform enables a shift in the paradigm of
current cancer therapy from a predominantly intracellular approach to an extracellular synergistic method
of targeting cancer. In the process, we demonstrate the synthesis of a novel type of CaCO3 nanoparticle,
its stabilization, the increase of pH in vivo, a mathematical justification and simulation, and the
subsequent inhibition of tumor growth and metastasis. By neutralizing the tumor extracellular
microenvironment, the platform aims to prevent tumor progression and metastasis as well as minimize the

ix

traditional intracellular based pathways of resistance. Because of the broad universal aspect of low
extracellular pH in cancer, particularly in the more malignant tumors, we expect this platform will also
have wide applicability, with particular potency on the most aggressive of cancers.

x

Chapter 1: Introduction

1

1.1. Cancer Therapy
In spite of the declaration of “War on Cancer” 40 years ago, cancer remains a major public health
concern worldwide, causing nearly 1 in 4 deaths in the US alone. 1,2 In 2013, 580,535 cancer deaths
are expected in the US. 1 These statistics point to the enormous challenges in winning the “War on
Cancer” and indicate the need to rethink treatment paradigms that will improve treatment
outcomes.

1.1.1 Molecularly targeted chemotherapeutics:
Cancer is now accepted as a disease caused by genomic instability and epigenetic factors. 3,4 This
understanding has ushered in a new set of drugs that target specific molecular pathways used by
cancer cells to proliferate and elude the host defense system. Through genomic, proteomic, and
metabolomics analyses, several highly successful molecularly targeted therapeutics have been
developed such as Dasatinib, which targets tyrosine kinases in chronic myeloid leukemia, and
Temsirolimus, which targets the mammalian target of rapamycin (mTOR) found in solid tumors
such as renal cell carcinoma.5,6 However, in spite of embodying the paradigm of most current
therapeutic research, targeted therapeutics are rarely used for curative intent. Indeed, most targeted
therapeutics require a specific subset of clinical patients to demonstrate efficacy.7 Given an
average development cost of about 1.8 billion dollars per drug, this inefficiency has clinicians
turning towards alternatives, such as screening old drugs for off-label use. 8 In addition, due to the
redundancy of intracellular pathways, cells are able to mutate around the targeted pathway,
developing resistance. Examples include Imatinib (Anti-BCR-ABL) and anti-Her-2 therapies,
whose mechanisms of resistance are now active fields of study. 9,10 Given the difficulties we face
with molecularly targeted chemotherapeutics, these findings support the need to re-explore the
hallmarks of cancer as a universal target for cancer therapy.
2

1.1.2 Hallmarks of cancer
Cancer is the disease of unrestrained growth and metastasis by cells within the body generally
induced by a sequence of genetic mutations that can be clonal (from a single cell origin) or
varied. 11 Cancers can effect patients at any point in the life of a human, with increasing
propensity with age.11 Although each cancer is relatively unique, with specifics based on its
mutation history, much of the resulting phenotype can be said to be common in various tumors
but different from the surrounding normal tissue.11 This is of strict importance because cancer,
unlike many prokaryotic or fungal infectious diseases, also shares a significant component of its
antigens with the host. This makes creating both novel compounds and treatments difficult for a
curative approach without also eliminating the host patients.
These unique hallmarks among cancers include: increased and limitless mitosis from self
sufficiency of growth signals, insensitivity to inhibitory signals, evasion of apoptosis, immune
evasion, tissue invasion, and metastasis, hypoxia, extracellular acidity, deregulated cellular
energetics and increased angiogenesis.11,12 Further, the tumor microenvironment, including
cancer associated fibroblasts, pericytes, cytokines, and extracellular matrix, play an important
role in cancer progression, metastasis and growth. 13 Metabolic hallmarks, such as the
deregulation of glycolysis, have resulted in a unique acidic extracellular environment that is both
important for tumor prognosis and for differentiating from other tissues.14 The tumor
inflammatory milieu creates a mutagenic environment, and can often induce the existing
surroundings to become pro-tumor contributing to immune evasion.15 Each of these unique
hallmarks, because of their commonality, has been targeted by nanomaterial based techniques for
both imaging and therapy.

3

1.1.3 Targeting the hallmarks of cancer for generalized chemotherapy:
Malignant tumors rely on several fundamental pathophysiological processes for survival.
Targeting these processes is the favored clinical approach because the agents can be widely used
to treat diverse cancer types. Thus, most clinical progress involves therapeutics targeted against
DNA replication, microtubules, and glycolysis. However, each of these methods has typically
severe side-effects. Anti-mitotic agents, for example, have deleterious effects on any rapidly
dividing normal cells, with life threatening implications from bone marrow loss that can lead to
immunodeficiency and life threatening infection.16 With only a few exceptions, these
chemotherapies are rarely curative and alternative compensatory metabolic pathways often lead to
drug resistance. For example, glycolysis inhibitors are not effective because this conserved
metabolic process is replaced by glutamine consumption from muscles, often leading to
cachexia.17,18

1.2

Extracellular acidic environment is a physiologic hallmark and

therapy target of cancer
In the face of these challenges, tumor extracellular acidity has been revisited as a potential target.
Models on tumor extracellular pH (pHe) demonstrate a significant relationship between tumor
invasiveness and the increased production of acid in most tumors.

19,20

To maintain normal

intracellular pH (pHi) and to promote growth by degradation of the extracellular matrix, tumor
cells actively transport the excess protons generated during enhanced glycolysis, the Warburg
effect, to the extratumoral environment.

21

This leads to a sustained acidic tumor environment,

with an average extracellular pH of 6.8, as opposed to the buffered and highly regulated interstitial
pH of about 7.4 in the vicinity of healthy tissue.22 Tumor cells actively use this 4 fold increase in
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hydrogen ion concentration to degrade the tumor matrix and thus sustain its growth.

20,21

This is

possibly due to an increase in matrix metalloproteinase activity at lower pHs. This realization, that
low pHe is an indispensable condition for tumor metastasis and malignancy, has increased interest
in its potential as a therapeutic target.23,24

1.2.1 Recent work on pH sensitive chemotherapeutics:
The acidic environment of cancer is a unique condition that can be targeted to treat diverse tumor
types. Groups have tried changing the low pH environment of tumors by either inhibiting carbonic
anhydrases or directly neutralizing the tumor acid environment via systemic administration of oral
sodium bicarbonate.

23,24

Both of these models have shown efficacy in in vivo animal models.24

However, carbonic anhydrases are important in normal cell physiology and given the vast class of
carbonic anhydrases available to tumors in their genetic material, whether the inhibitors can
overcome the system’s redundancy, such as that seen in anti-glycolytic drugs, remains unknown.
The systemic administration of untargeted oral sodium bicarbonate to directly neutralize the acid
environment of tumors is not practicable in clinics because of the potentially severe consequences
of metabolic alkalosis.25 In addition, both of these treatments modify pH only temporarily.

1.2.2 Nanomaterials as a potential method for neutralization.
Nanomaterials, and in particular, nanoparticles, have been able to deliver toxins locally that
otherwise have systemic side-effects locally to a tumor site. Nanoparticles have been made to be
pH sensitive for the delivery of other chemotherapeutics as well. However, nanomaterials have not
yet been designed to change proton concentrations themselves in vivo. As such they may be a
promising technology to enable the practical application of changing pH in tumors in vivo as a
therapeutic paradigm.

5

1.3 Nanomaterials as a medically significant tool and technology
Indeed, in the most recent years, nanomaterials in general, have been used for tackling the
question of treating cancer. A nanomaterial is defined as a particle or structure, in its broadest
form < 1 𝜇m, though generally produced in the range of 10 nm to 500 nm. Nanomaterials can
come in a variety of shapes and share a series of interesting properties compared to their
macroscopic peers, particularly as it relates to biological systems. The average cell in the body is
10 𝜇m, and has the general capability to ingest nanoparticles < 1𝜇m in size. 26 This has resulted
in a series of advantages for classical delivery. Nanomaterials can be made to respond directly to
the hallmarks of cancer, such as pH. (Figure 1.1)

Figure 1.1: Targeting the hallmarks of cancer
Nanomaterials are unique in their ability to respond to particular stimuli and targets. Antibodies,
peptides, and aptamers, can all target growth factor receptors, or markers of angiogenesis. Using
material and unique properties of nanoparticles, nanomaterials are uniquely capable of
responding to stimuli such as hypoxia, pH, and enzymatic activity.

6

1.3.1 Currently used nanomaterials in medicine
Currently existing nanomaterials have had significant use in material science, paints, and other
manufacturing processes. 27,28 In addition, nanomaterials have already been applied for medical
applications and reached a level of commercialization, including liposomes for drug delivery,
polymeric nanoparticles for blood brain barrier, nanoemulsions and drug solubility enhancers,
antibiotics, sunscreen, and quantum dots for imaging, and silica particles for fluorescence. 28
Nanomaterials as such have been primarily used in therapeutic applications, but it is clear that
the capability of taking to a commercial medical outlet remains a possibility. Environmental and
toxicity concerns also continue to be of interest and study. 27 While most nanomaterials have
been used for intracellular delivery and targets, interesting and further trends then for
nanomaterials lie in pushing into extracellular environment modulation. Nanomaterials may be a
practical method of changing pH.

7

1.4 Advantages of nanomaterials in medicine
1.4.1 Pharmacokinetics
A significant advantage of nanomaterials refers to its pharmacokinetic properties, both in
increasing the duration of effect by agents and reducing the necessary dose. Pharmacokinetics
relates to the distribution, spread, and time course of material remaining in the body. Single
molecule drugs range in the size range of approximately < 1 nm, and are generally cleared by
both glomerular filtration of the kidneys, and liver filtration and removal via bile. As a result of
this, free drug concentrations can clear quickly, in < 24 hours. 29,30 Nanoparticles are generally
large enough to avoid glomerular filtration, but small enough to leak out into the tumor
microenvironment. Addition of stabilizing molecules such as polyethylene glycol or
polysaccharides on the nanoparticle surface can dramatically improve blood circulation times
and avoidance of the macrophages of the reticuloendothelial system. This property in particular
has been heavily used to enhance the half life in blood of a number of otherwise rapidly excreted
therapeutics. Examples of this phenomenon include Doxil, the liposome formulation of
doxorubicin. 29 In imaging applications, dendrimers nanoparticles have been used to prolong the
clearance rate of gadolinium contrast agents. 31 In addition to contrast agents, nanoparticles can
be functionalized with drugs and used as vehicles for delivery for diseases such as cancer32. In
doing so they can alter the pharmacokinetics of drug release, creating more therapeutic potential.
Multiple nanoparticle formulations have been used for cancer therapy, including a paclitaxelloaded poly(lactic-co-glycolic) polymer nanoparticles, doxorubicin-cojugated PLGA
nanoparticles, dendrimers with 5-Fluorouracil incorporated, lipid-based anti-neoplastic
nanoparticles, and gene-delivering polyethylenimine nanoparticles33. Tuning size is thus very
important for biodistribution.
8

1.4.2 Pharmacodynamics
Another advantage is in the pharmacodynamics of nanoparticles. In traditional
pharmacodynamics, a free drug is an active drug, while a bound drug is inactive. A nanoparticle
can be treated like an effective bound drug. Tuning release from the nanoparticle as a result
becomes a potent way to increase therapeutic efficacy at local biological sites while also
reducing off-target side-effects. This advantage of nanomaterials has driven a large degree of
clinical efficacy by increasing the absolute amount of the underlying drug dose a person can
tolerate, such as seen in Doxil, the liposome form of doxorubicin, or in more recent drugs such as
in Parkinson’s. 34,35

1.4.3 Surface area to mass ratio
Surface area to mass is related as a function of 1/r, where r is the radius of the material. As a
result, nanomaterials have a significantly increased surface area to mass ratio as compared to
their macromaterial counterpart. The interface of a particle’s surface to its environment is the
basis on which a large number of chemical reactions can occur. Per unit mass, increasing the
surface area to mass ratio thus greatly enhances the available reactant in the particle to the
environment. This phenomenon has been used to create sensitive changes in the nanoparticle
when in particular environments such as pH 36,37 , as well as potential enhance binding
phenomenon due to multivalency from multiple surface ligands on a single particle.38 (Figure
1.2)

9

Figure 1.2: Microscopic vs Macroscopic nanomaterials
An important element of nanoparticles compared to its microparticle counterpart is the increased
surface area to volume ratio. a) Representation of a microparticle of 1 𝜇m diameter b)
Representation of the number of 100 nm diameter particles able to fit in the volume of a 1 µm
diameter particle, which is nearly 10x more surface area.

1.4.4 Enhanced Permeation and Retention:
In cancer and inflammation, vessels of the body can become leaky for a variety of reasons,
including rapid angiogenesis, as well as a way for immune cells to enter the local area.29 This has
been proven by both casts and surface scanning images demonstrating the gaps.29 More recently,
this permeability has been reported to not be only static, but also have a temporal dynamic
nature, with reports of bursts of fluid from the blood into the tumor interstitial area. 39 Further, in
cancer, in particular, the growth of cells with a lack of traditional coordination, often means the
lack of lymphatics, the body’s natural sewage system. As a result, fluid and particles that enter
via these leaks, tends to not be cleared as rapidly as they would be in normal tissue. 40 These
leaks are size dependent, and have been found to hover around the nanoparticle size range (10-

10

500 nm) depending on disease or cancer type. This as a result causes a selective increase in the
concentration and aggregation of nanoparticles within the area of diseased tissue, allowing a
natural targeting due to size. 40 In addition, because of the size, nanoparticles can have increased
diffusion capabilities into the tissue as compared to the macromolecular constructs, with smaller
particles going farther. The lower limit of size is limited finally by the glomerular apparatus. The
upper limit of size is limited by this leakiness of blood vessels. (Figure 1.3)

Figure 1.3 Pharmacokinetics: Evading glomerular filtration and tumor retention by
enhanced permeation and retention (EPR)
Nanoparticles are unique in how their size affects their in vivo performance. a) (Left) Small
molecules (triangles) filter easily in the fenestrations seen in the glomerular renal filtration
system, whereas larger nanoparticles can avoid this filtration and continue on to the target. b)
(Right) Representation of the EPR effect, where, due to their size, nanoparticles selectively
penetrate into the tumor region but not into normal tissue. In addition, the lack of lymphatics in
the tumor prevents clearance causing increased size-induced retention.
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1.5. Capabilities of Nanoparticles
1.5.1 Targeted delivery of compounds
Targeting of nanoparticles can be done both passively, relying on the size effect induced EPR
effect, as well as by adding targeting groups, whether antibodies, peptides, or aptamers targeting
specific aspects such as angiogenesis, hypoxia, or protein upregulation like folate or EGF. 41-43
These targeting groups can enhance the percentage of nanoparticles in an area, and are valuable
directors in inducing cellular uptake and directing cellular delivery. 38,44

1.5.2 Sensing the environment- nano tuning delivery
A consequence of the increased surface area to mass ratio is an increased ability to sense
environments. This allows an increased reaction rate at the surface for a variety of chemical
reactions including protonation, hydration, protease degradation, or a change in charge of the
particle. This change effectively signals a difference externally whether for the delivery of a
drug, or for imaging purposes. 45-48 Examples include pH sensitivity by nanoparticles to the
acidity in the tumor microenvironment, (approximately a pH of 6.5) for therapy. 37,49-52
Nanoparticles have not yet been used to modify this environment.

1.5.3 Entering and modifying the intracellular compartment
The intracellular compartment is composed of both the cytosol and a variety of organelles. By
and large, nanoparticles enter the cell via a lysosomal pathway, with a variety of specific
endocytosis mechanisms. The lysosome itself has a low pH (about 5), as compared to a cytosolic
pH have 7.2. Multiple nanoparticles have thus been developed to escape the lysosome, using the
proton sponge effect, an effect of using poly-amines and bases to break the barrier by osmotic
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lysis.

53-57

Other groups have used methods such as viruses to deliver cargo to the cytosol,

external stimuli to break the lysosomal membrane for delivery, and even others rely on passive
diffusion across membranes post release in the extracellular environments, such as hydrophobic
chemotherapies or proton channels that already exist. 58-60 All of these methods deliver
components that end up changing the intracellular compartment in either composition, or more
commonly delivering to change gene products (miRNA or siRNA) themselves. 53,61,62

1.5.4 Quenching and Imaging
Nanoparticles, for imaging, can also serve as a quenching sink, a consequence of being able to
deliver and generate an easy area for binding. This phenomenon has been heavily used for gold
in particular, as well as other nanoparticle bases.63-68 In addition, nanoparticles are capable of
triggered release and as a result do well as a prodrugs and activatable imaging agents. 36,37,69-71

1.5.5 Modifying the extracellular compartment
The extracellular environment has become of increasing interest because of its importance in
tumor growth and metastasis. Trying to target and change this area howevser has only recently
become of recent interest. The question remains whether the advantages held by nanoparticles
can be used to enable a new therapeutic paradigm involving increasing the local pH of tumors in
vivo.

13

1.6 Aims of the dissertation.
Given this context, the goal of this dissertation was to explore the effects of pH on tumor growth
through the development of a novel pH neutralizing nanoparticle. Accordingly, we investigated the
following hypotheses.
Chapter 2: The acidic extracellular pH of tumors has a downstream effect on surrounding stromal
fibroblasts.
Chapter 3: The mathematical simulation of CaCO3 in vivo will predict the ability to change pH
selectively in vivo
Chapter 4: CaCO3 can be synthesized as a nanoparticle
Chapter 5: CaCO3 nanoparticles have minimal toxicity and have a systemic biodistribution that reaches
the tumor
Chapter 6: Systemic administration of CaCO3 nanoparticles can increase pH in vivo and inhibit tumor
growth and metastasis.

14
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Chapter 2: Effect of pH on the extracellular
environment and surrounding stromal cells
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Chapter Summary

We explored the effect of the acidic microenvironment on surrounding stromal cells. Octamerbinding transcription factor 4 (OCT-4) is an important marker of cellular de-differentiation that
can be induced by environmental stressors, such as acidity. Here we demonstrate that chronic
acidic stress in solid tumors induced OCT-4 expression in fibroblasts and other stromal cells in
four tumor models. The results have implications for how tumors utilize pH modulation to
recruit associated stromal cells, induce partial reprogramming of tumor-associated stromal cells,
and respond to therapy. It demonstrates the importance of acidity on tumor growth.
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2.1 Introduction
Tumor-stromal interactions play important roles in tumor growth and metastasis with
direct impact on extracellular matrix enzymes, cytokines, matrix polymers such as collagen and
hyaluronic acid derivatives, hypoxia, and pH. 1-5 Previous studies have shown that stromal cells,
such as cancer-associated fibroblasts and perivascular cells, participate in tumor metastasis and
growth. 6,7 A vexing question is how tumors recruit and alter stromal cells, including fibroblasts,
from normal tissue during cancer growth and metastasis. 8-10
The cancer microenvironment replicates in many ways the characteristics of normal stem
cell environments.11-13 Several factors, such as hypoxia and the acidic environment found in the
cancer stem cell niche, are also stressors on cell metabolism and division.11,14 Literature suggests
that these same stressors can induce at least a partial reprogramming of fibroblast cells in vitro,
resulting in the expression of OCT-4 in culture under conditions of metabolic stress. 15 Both in
vivo and in vitro studies have shown that OCT-4 mediates cellular development. Given that the
in vivo microenvironment of many solid tumors is weakly acidic (pH 6.5)16-19, we hypothesized
that acid-mediated chronic mild stress would induce a partial reprogramming of stromal cells in
vivo, as indicated by increased OCT-4 expression. Our results show that in vitro replication of
the chronic mildly acidic solid tumor environment induced OCT-4 expression in murine
fibroblasts. We also demonstrated that OCT-4 expression increased in fibroblasts and other
supporting stromal cells within tumor xenografts. This expression of OCT-4 may explain some
of the stem cell-like phenotypes of stromal cells within the tumor microenvironment.
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2.2 Methods
2.2.1 Statement on Ethics
All animal experiments were conducted in accordance with the approved guidelines for the care
and use of laboratory animals in research, and the protocol was approved by the Washington
University Animal Welfare Committee.

2.2.2 Immunofluorescent staining
Cells or tissues were stained per the manufacturer’s protocol using rabbit polyclonal (ab19857,
Abcam, Cambridge, MA; 1:200 dilution) or murine anti-OCT-4 (ab91194, Abcam, Cambridge,
MA; 1:200 dilution), and rat anti-Vimentin (ab115189, Abcam, Cambridge, MA; 1:200 dilution).
Secondary antibodies were Allophycocyanin anti-mouse IgG (A-865, Life Technologies, Grand
Island, NY; 1:1000), AlexaFluor 555 anti-rabbit IgG, and anti-Rat IgG AlexaFluor 647 (Abcam,
Cambridge, MA; 1:1000 dilution). Cells were visualized with an Olympus FV1000 Confocal
Microscope using 488 nm, 543 nm, or 633 nm for excitation. Tissue was visualized with an
Olympus BX51 upright epifluorescence microscope (Olympus America, Center Valley, PA)
using excitation/emission filters of 480 nm / 535 nm, and 620 nm / 700 nm.

2.2.3 Tumor model growth
BxPC-3, MDA-MB-231, and EMT-6 cells were injected subcutaneously into the dorsal flanks of
athymic nude mice, while 4T1luc cells were injected into Balb/c mice. Mice were sacrificed
when the tumors were between 0.5 and 1.5 cm in diameter. In certain cases, tumors may have
had exposure to the near-infrared tumor imaging agent cypate prior to excision. Tumors were
excised based on gross appearance and frozen in OCT media. The average pH in 4T1 tumor
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models was 6.8 +/- 0.1 pH units, as measured by an invasive probe (5 mm probe). The average
pH level in EMT-6 and BxPC-3 tumors was not measured, previous studies reported acidity in
BxPC-3 and EMT-6 tumor models and the importance of the pH for chemotherapy resistance.19
Tissue sections were cryosectioned at 10 𝜇m thickness. Tissue was visualized with an Olympus
BX51 upright epifluorescence microscope (Olympus America, Center Valley, PA) using
excitation/emission filters of 480 nm / 535 nm, and 620 nm / 700 nm.

2.2.4 Cell culture
MDA-MB 231, 4T1luc, and BxPC-3 tumor cells, and 3T3-GFP fibroblasts were cultured alone
or in co-culture in acidic (pH 6.5), slightly acidic (pH 6.8), or non-acidic (pH 7.4) media
(DMEM + 10% FBS + 1% Pen Strep) in 8 well slides. Acidic media was created by titrating
DMEM + 10% FBS + 1% Pen Strep media with 1 M HCl to the desired pH range. Slides were
incubated for 7 days without any modifications in 5% CO2 at 37oC, after which they were
stained for OCT-4. A summary of techniques can be found in Figure 2.1.

2.2.5 Longitudinal study
Cells were cultured as described above in normal media overnight and then switched to acidic
conditions at day 0, 1, 3, and 5 and incubated until day 7 prior to immunostaining.

2.2.6 3T3 Fibroblast growth in nude mice
3T3-GFP Fibroblast cells were grown in T75 flasks under either HCl titrated, pH 6.5 conditions,
as described above, or in pH 7.4 media for 7 days, or grown in T75 flasks under normal
conditions overnight. Cells were trypsinized and injected in a 50% matrigel/PBS matrix. For
each “tumor” injection site, 1 million cells from the above three categories were used. Mouse 1
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received the acid treated cells on its left flank and 7 day pH 7.4 treated cells in its right flank.
Mouse 2 received the acid treated cells on its left flank and 1 day pH 7.4 treated cells in its right
flank. Mouse 3 received 7 day control cells on its left flank and 1 day pH 7.4 treated cells in its
right flank. GFP images were taken 2 weeks later using the ART Optix MX3 system.

Figure 2.1: Methodology/Summary for OCT-4 induction in vitro. Describes the methods
section schematically. (a) 3T3-GFP+ can be treated with pH 6.5 treated medium leading to the
strongest OCT-4 expression, with reduced expression going towards 7.4. (b) 3T3-GFP+ can be
co-cultured with a tumor cell line and induce the same effect with the strongest OCT-4
expression at pH 6.5.
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2.3 Results
2.3.1 Exposure of cells to acidic environment induces OCT-4 expression in
vitro
We used four tumor cell lines for this study: (1) the human breast cancer cell line MDA-MB-231
is OCT-4 positive and expresses the OCT-4 inducing leukemia inhibitory factor, LiF20; (2) the
murine mammary carcinoma EMT-6 undergoes epithelial-mesenchymal transition; (3) the
human pancreatic adenocarcinoma BxPC-3 has not, to our knowledge, been shown to express
OCT-4 ; and (4) the murine breast cancer model 4T1luc is an aggressive tumor model with
significant drug resistance. We first determined if the tumor cells could induce OCT-4
expression in nontumor cells under normal physiologic pH. Using BxPc-3 and MDA-MB-231
cells, we cultured GFP transfected 3T3 fibroblast cells (non-tumor cells) in pH 7.4 media for 7
days in the presence or absence of tumor cells. In the absence of cancer cells, OCT-4 expression
in the 3T3 cells did not increase over time (Figure 2.2a). In contrast, co-culture of these
fibroblasts with tumor cells at pH 7.4 resulted in increased OCT-4 expression (Figure 2.2 b, c).
The enhanced nuclear localization of OCT-4 indicates that tumor cells can facilitate OCT-4
expression in surrounding healthy tissue under normal physiological pH.
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Figure 2.2: Simulation of tumor-associated pH environment in vitro. Confocal imaging of rabbit
polyclonal anti-OCT4 (red) staining and anti-vimentin (green) in 3T3 cells under various conditions.
Fibroblasts (a) incubated in pH 7.4 media, (b) co-cultured with MDA-MB-231 cells in pH 7.4 media, (c) cocultured with BXPC-3 in pH 7.4 media, (d) incubated in pH 6.5 media, (e) co-cultured with MDA-MB-231
cells in pH 6.5 media, (f) co-cultured with BXPC-3 breast cancer cells in pH 6.5 media. All the cells were
incubated for 7 days with no changes in media. Magnification is 20x. Scale bar is 100 𝜇m.
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A previous study showed that cells cultured in a highly acidic environment (pH 5) showed
increased OCT-4 expression.15 Because the extracellular pH of solid tumors rarely falls below
pH 6, we investigated whether OCT-4 expression could be induced in cells cultured in a more
physiologically relevant, mildly acidic medium (pH 6.5), similar to the extracellular pH of solid
tumors. GFP transfected 3T3 fibroblast cells were cultured in acidic (pH 6.5) media for 7 days in
the presence or absence of tumor cells. A high level and intense nuclear localization of OCT-4
expression was observed in both the presence and absence of tumor cells (Figure 2.2 d-f),
suggesting the possibility of cell reprogramming under these conditions. Co-staining with
vimentin shows strong cytoplasmic vimentin positivity confirming the fibroblast origin of the
cells (Figure 2.2). The percentage of OCT-4 positive cells sequentially increased over time
(Figure 2.3), indicating that chronic exposure of these cells to acidic environments such as those
found in some solid tumors, provides a potential pathway to induce cellular stress to surrounding
healthy cells. In addition, there is an inverse correlation of OCT-4 expression with acidity, OCT4 intensity increasing as pH decreases from 7.4 to 6.5 (Figure 2.4). Very few BxPC-3 and MDAMB-231 (GFP-negative) cells were observed because these cells do not remain adherent during
staining. Similar results were obtained when cells were stained using a second OCT-4 antibody
(Figure 2.5). Incubation with non-tumor cell lines, such as primary mammary epithelial cells
(PMEC), under acidic conditions showed OCT-4 expression in both cell lines, while no OCT-4
expression was seen under non-acidic conditions. (Figure 2.6)
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Figure 2.3: Time course of OCT-4 expression. (a) OCT-4 expression of GFP+ fibroblasts cultured
for 7 days in normal pH 7.4 media. (b) OCT-4 expression MDA-MB-231 cells, positive control. (c)
OCT-4 expression of GFP+ fibroblasts cultured for 6 days in normal pH 7.4 media and 1 day in pH
6.5 media. (d) OCT-4 expression of GFP+ fibroblasts cultured for 4 days in normal pH 7.4 media and
3 day in pH 6.5 media. (e) OCT-4 expression of GFP+ fibroblasts cultured for 2 days in normal pH
7.4 media and 5 day in pH 6.5 media. (f) OCT-4 expression of GFP+ fibroblasts cultured for 7 days in
pH 6.5 media. Red represents OCT-4+ cells, and green represents GFP+ fibroblasts. Scale bar
represents 100 𝜇m.
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Figure 2.4: Effect of pH gradient on OCT-4 expression in 3T3 fibroblast cells. (a)
Fibroblasts incubated in media (pH 7.4) for 7 days with no changes in media (b) Fibroblasts
incubated in acidified media (pH 6.8) for 7 days with no changes in media, (c) Fibroblasts
incubated in acidified media (pH 6.5) for 7 days with no changes in media, (d) Fibroblasts
cocultured with MDA-MB-231 breast cancer cells incubated in acidified media (pH 7.4)
incubated for 7 days, (e) Fibroblasts cocultured with MDA-MB-231 breast cancer cells
incubated in acidified media (pH 6.8) incubated for 7 days, (f) Fibroblasts cocultured with
MDA-MB-231 breast cancer cells incubated in acidified media (pH 6.5) incubated for 7 days.
Scale bar is 100 um. Red represents OCT-4+ cells, and Green represents Vimentin+ fibroblasts.
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Figure 2.5: Murine monoclonal anti-OCT 4 staining in 3T3 fibroblast cells under different
conditions. (a) OCT-4 staining of GFP+ fibroblasts cultured in normal media for 7 days. (b)
OCT-4 staining of GFP+ fibroblasts cultured in acidified media (pH 6.5) for 7 days. (c) OCT-4
staining of GFP+ fibroblasts co-cultured with MDA-MB-231 tumor cells in acidified media (pH
6.5) for 7 days. Red represents OCT-4+ cells, and Green represents GFP+ fibroblasts. Scale bar
represents 100 𝜇𝑚 and is at 40x magnification. Note Supplementary figure 1b is a replicate of
figure 2f and shown here again primarily for comparison.
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2.6: Co-Culture of Fibroblast-GFP cells with PMEC cells. (a) Co-culture of primary
mammary epithelial cells with 3T3-GFP-fibroblasts for 7 days, and stained with OCT-4. (b) Coculture of primary mammary epithelial cells with fibroblasts in acidified media for 7 days. Cells
without GFP are primary mammary epithelial cells.
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2.3.2 Ex vivo expression of OCT-4 in tumor tissue
We next investigated OCT-4 expression in xenografts from three tumor models: 4T1luc, EMT-6,
and BxPC-3. Cardiac muscle was used as an in vivo negative control due to the low propensity of
that tissue to stem cell activity. Expectedly, we did not detect OCT-4 expression in heart tissue
(Figure 2.7). Tumors were 0.5 cm to 1.5 cm in size on excision. The average pH level in 4T1
tumor models was 6.8 +/- 0.1 pH units as measured by an invasive 5 mm probe. This is
consistent with previous studies, which reported acidity in BxPC-3 and EMT-6 tumor models
and the importance of the pH for chemotherapy resistance.19 In contrast, OCT-4 expression was
detected in all three tumor tissues (Figure 2.8) and was localized to certain cells in and around
the tissue section. The entirety of the section was considered to be tumor. These results suggest
that OCT-4 expression spans multiple human and murine tumor types. OCT-4 expression,
however, seems to be sparse, with only a few tissue areas showing positive staining.
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Figure 2.7 Negative control for anti-OCT-4: (a) Heart muscle stained for anti-OCT-4.
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Figure 2.8: Murine Monoclonal anti-OCT-4 staining of tumor and stroma. Oct-4
expression (red) in (a) 4T1luc tumor; (b) EMT-6; (c) 4T1 luc tumor margin; (d) BxPC-3
tumor. Scale bar is 500 𝜇m.

2.3.3 Identification of fibroblasts expressing OCT-4 in tumor tissue
Fibroblasts are an important and common cell type in cancer stromal tissue. To verify that the
OCT-4 positive cells were fibroblasts, we co-stained tissues for the fibroblast marker vimentin
and OCT-4 (Figure 2.9). Co-staining indicated that OCT-4 localized in the vicinity of vimentin
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positive cells, with several instances of co-localization (yellow, Figure 2.9), suggesting that these
cells are indeed fibroblasts. Our data suggest the presence of three populations of cells: OCT-4+,
vimentin+, and a subset of cells positive for both OCT-4 and vimentin. MDA-MB-231 is a
human breast cell carcinoma cell line that has high intrinsic expression of OCT-4. We did not
assess subcellular distribution of OCT-4 or vimentin in the tissue sections.
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Figure 2.9: Co-staining for OCT-4 (red) & Vimentin (green) in tumor tissues. 10x bright field
images with crop-outs being subsets of the original 10X images. (a) Co-staining of BxPC-3 tumor
tissue (b) Staining of MDA-MB-231 tumor tissue (c) Staining of EMT-6 tumor Yellow indicates areas
of co-localization. Scale bar represents 500 𝜇𝑚 for the low magnification image, and 100 𝜇m for
magnified regions.
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Literature values and independent pH measurements in our laboratory show that the pH in the
tumor area ranges from 6.5-7.0. By chronically maintaining the extracellular pH below 7, cancer
cells can stimulate non-tumor cells to reprogram via pH-related stress. This process could aid the
recruitment of surrounding cells into the tumor matrix.2,20

2.4 Discussion
The extracellular pH of tumors has been implicated in the metastasis and behavior of
tumor cells, and changes in this pH could modify the downstream behavior of cancer. 18 To our
knowledge, this is the first report of the expression of OCT-4 in the vicinity of tumors,
particularly in supporting stromal cells. Stress based in vitro OCT-4 expression has been reported
previously for stem cells.14,21 Our data suggests that chronic mild acidity, which is present in the
tumor environment along with other stressors, is capable of inducing OCT-4 expression in
murine fibroblasts and may be sufficient to induce OCT-4 expression in vivo. These
observations suggest that tumor cells in vivo may be capable of reprogramming surrounding
stromal cells using environmentally mediated factors.
There are a few caveats to the above platform. The tumors were all xenografts and it is
not known if this phenomenon occurs in spontaneous tumor models. We focused primarily on
murine fibroblasts to facilitate in vivo assessment of the phenomenon with the same cells. It is
also unclear if the in vivo OCT 4 expression changes with tumor size in this study.
Ex vivo histology showed expression of OCT-4 in cells that are not fibroblasts. Other
than MDA MB-231 tumors, which had high intrinsic expression of OCT-4, the positive cells did
not make up the bulk of the tumor mass. We posit that these cells may be endothelial or other
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epithelial cells in the stromal region, or perhaps some small subset of cancer cells. This
hypothesis is supported by in vitro expression of OCT4+ in PMEC cells, a primary mammary
epithelial cell line, under acidic conditions.
This report offers observational evidence that mild acidity does induce some degree of OCT-4
expression in vivo, therefore confirming previous findings about stress based OCT-4 expression.
However, it is not clear how long these cells maintain the OCT-4 expression nor if the
expression induces any other pluripotent stem cell phenotype. To rule out the possibility of
artifact, we tested both a mouse monoclonal and a rabbit polyclonal anti-OCT-4 antibody. We
observed similar results with both antibodies, although OCT-4 localization at times alternated
between cytoplasmic (murine monoclonal) and nuclear (rabbit polyclonal), depending on the
type of antibody used (Figure 2.2, Figure 2.5).
Fibroblasts are traditionally considered to be strong supporting actors in the tumor
microenvironment. The concept that chronic physiological extracellular acidity can have
significant effects on the expression of reprogramming markers, such as OCT-4 both in vitro and
in vivo, suggests a possible mechanism for the phenotypic changes in cancer associated
fibroblasts. One report indicates that acidity may actually transform fibroblasts into cancerous
tissue.22 Some preliminary data (Figure 2.10) demonstrate that implantation of these acid treated
cells induces tumor growth in athymic nude mice. For this study, fibroblast cells were not cocultured with tumor cells. Further, the concept that acid mediated stress can induce the presence
of factors that cause reprogramming in vivo raises the question of what happens if intratumoral
pH is changed in vivo. Indeed, pH changes in vivo can inhibit tumor growth.23
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Figure 2.10: Dorsal GFP images of in vivo growth of acid treated fibroblasts. (a) GFP image
of mouse 1: acid treated 3T3 cells on its left flank, and 7 day pH 7.4 treated 3T3 cells in its right
flank. (b) GFP image of mouse 2: acid treated 3T3 cells on its left flank, and 1 day pH 7.4
treated 3T3 cells in its right flank. (c) GFP image of mouse 3: 7 day control 3T3 cells on its left
flank, and 1 day pH 7.4 treated 3T3 cells in its right flank.
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Overall, this study reveals that the stroma of tumors express OCT-4. Based on in vitro
data, it is likely that chronic mild acidic stress could facilitate cell reprogramming. Given the
ubiquity of extracellular acidic environments in some solid cancers, this process could be a
common occurrence in vivo. We demonstrated that pH evidently has an important effect on both
cancer cells and the supporting stroma. These results further support the relevance of the
extracellular matrix and its environment to cancer behavior, prognosis, and therapy. In particular,
the increasing evidence that tumors actively maintain an extracellular acidic environment implies
a causative role for pH in tumor survival and proliferation. There is thus an intersection between
the significant work involved in cancer metabolomics, the Warburg effect, and the tumor
microenvironment. Future work will focus on replicating this observed phenomenon in vivo in
human subjects, as well as developing a platform to modulate this acidic pH in vivo.
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Chapter 3: Mathematical simulation of a pH
modulating nanoparticle: Identification of Calcium
Carbonate as an ideal candidate for increasing pH in
vivo
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Chapter Summary
Modeling the pH change in vivo from a nanomaterial can be used to identify the ideal material
for increasing pH in vivo, as well as give insight on expected pH changes and pharmacokinetics.
In this chapter, we demonstrate a unique physiological pH sensitivity by CaCO3 due to the high
stable calcium concentration in vivo. In particular, the results of this chapter predict that CaCO3
nanoparticles will increase pH only in physiologically acidic regions without any resultant
metabolic alkalosis. In the process, we develop a simulation for nanoparticle distribution and
degradation.
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3.1 Introduction:
Recently, tumor extracellular acidity has been revisited as a potential target for cancer
therapy. Models on tumor extracellular pH (pHe) demonstrate a significant correlative relationship
between tumor invasiveness and the increased production of acid in most tumors. 1,2 To maintain
normal intracellular pH (pHi) and to promote growth by degradation of the extracellular matrix,
tumor cells actively transport the excess protons generated during enhanced glycolysis, the
Warburg effect, to the extratumoral environment.

3

This leads to a sustained acidic tumor

environment, with an average extracellular pH of 6.8, as opposed to the buffered and highly
regulated interstitial pH of about 7.4 in the vicinity of healthy tissue.4 Cells are thought to actively
use this 4 fold increase in hydrogen ion concentration to degrade the tumor matrix and thus sustain
its growth.

2,3

This has led to a hypothesis that low pHe may be important for inducing tumor

growth and metastasis.
Local extracellular acidity has been demonstrated to have active effects on a variety of
tumor and stromal cells. For instance, in vitro and in vivo trials have demonstrated immunologic
anergy in cytotoxic T cells suggestive of possible reasons for tumors avoiding immunosurveillance
in spite of the high lymphocytic presence in many tumors.

5,6

Other trials have demonstrated the

upregulation of a variety of proteins, including p53 and p21, when placed under acidic conditions
in vitro.

7,8

In addition, modulating extracellular acidity appears to change chemotherapy

sensitivity in tumors putatively due to changes in charge of drug molecules and intracellular
signaling changes downstream. 8-10 Given that pH in cancer can follow a wide range (5.6 - 7.0)4,8,
depending on type and size, clinical variability seen under chemotherapy may be due to underlying
pH differences.
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Although ample evidence suggests that extracellular pH plays an important role in tumor
growth and metastasis, most studies modulating extracellular pH in vivo have been impractical to
implement clinically. We explore herein using a nanoparticle approach to modulate intratumoral
pH. One candidate includes CaCO3. CaCO3 has a low solubility in water, allowing its presence in
nanoparticle form within aqueous solutions11-15 and relatively high pKa of 9, ensuring rapid pH
increase under acidic conditions. In addition, CaCO3 can deliver 9.03*106 protons per 100 nm
particle, a thousand fold increase over dendrimeric approaches in terms of capacity. Other groups
have used CaCO3 particles for acid sensitive drug delivery11-13,15 suggesting it is a prime candidate
for buffering only in tumor acidic regions. CaCO3 also has the additional advantage of being
composed of natural products found in the body, and because it follows basic chemistry for rate
equations, the dissolution and solubility in vivo can be simulated easily. Nevertheless,
mathematical models do not yet exist to predict what change of pH would occur in vivo.
Nanomaterials remain a largely empirical science. Much of the synthesis and production
has been done by trial and error. Although modeling of polymer growth and kinetics are well
known, atom by atom based modeling breaks down at the greater than ten nanometer size range
to become non-practical due to data size and computing time constraints. As such relatively little
though has been done to simulate and then predict what changes will occur in vivo post
nanoparticle administration.
There are however a few principles that have been established to understand dynamics
based on observations, including the importance of surface charge and functionalization to
stability. Thus far modelling has been applied to networks of hydrogels16 such as nanoparticle
transport in coronary arteries 17, modeling of particle erosion and drug release 18-21, and kinetics
of aggregation for gold nanoparticles 22. Simulations thus far have largely focused on using
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chemical engineering techniques, diffusion laws, and mass transfer equations, or modeling based
on existing data. These may allow for predictions of behavior, including elements such as pH
response in vivo that can guide design and application.23
CaCO3 nanoparticle diffusion in the tumor, and its potential subsequent effect on pH has
not yet been simulated. Doing so would provide a mathematical model to explain its diffusion and
change in pH under varying tumor circumstances, potentially gleaning an understanding of how
to improve its efficacy in changing tumor pH in vivo.
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3.2 Methods
3.2.1 Overall methodology of the simulation of CaCO3 dissolution in vivo.
Simulations were run in MATLAB using a numerical iteration approximation. Equations (1-6) are
derived from a tissue cylinder model of diffusion and diffusion of CaCO3 from a nanoparticle under
the conditions of constant infusion. Equations (5) and (6) were used to determine the initial CaCO3
and pH distributions in the tissue cylinder model. Changes in CaCO3 and pH were then numerically
approximated using equations (3) and (4).

𝑪𝒂𝑪𝑶𝟑 (𝒔) ⇋ 𝑪𝒂𝟐+ + 𝑪𝑶𝟐−
𝟑

(𝑲𝒂𝟏 = 𝟒. 𝟒𝟓 ∗ 𝟏𝟎−𝟕 )

(1a)

𝟐−
+
−𝟏𝟏
𝑯𝟐 𝑶 + 𝑯𝑪𝑶−
)
𝟑 ⇋ 𝑯𝟑 𝑶 + 𝑪𝑶𝟑 (𝑲𝒂𝟐 = 𝟒. 𝟔𝟗 ∗ 𝟏𝟎

(1b)

𝑯𝟐 𝑶 + 𝑯𝟐 𝑪𝑶𝟑 ⇋ 𝑯𝟑 𝑶+ + 𝑯𝑪𝑶−
𝟑

(1c)

Solubility (𝐂𝐛 ) = √
𝒅𝑪
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(𝟓)

[𝑯+ ]
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(𝟔)

The solubility of CaCO3 (Cb), in equation (2) is a function of pH, the solubility product (Ksp),
and equilibrium constants Ka1 and Ka2, obtained from equations (1a, 1b). The rate of change in
CaCO3 concentration (C) and in particle radius (r), seen in equation (3), are derived from Fick’s
law, and is a function of the diffusion coefficient (D), the surface area of diffusion (A), the distance
of diffusion (d) estimated at 0.1 mm, the solubility of CaCO3 (Cb), the volume of the tissue cylinder
(C), and the concentration of CaCO3 in vivo (Cs). For equation (4), we simplified equation (3) by
approximating A/V to 1/L, where L is the length of the tissue cylinder, estimated at 1 mm. The
change in concentration of protons can then be converted to a change in a pH of a buffer by dividing
by buffering constant, B= 28 mM/pH.35
For equation (5), Rcmax was empirically determined by starting at the maximum degradation
rate in the tissue at pH of 6.65 and then multiplying by a correction factor until the distribution of
CaCO3 appeared optimal, in this case approximately 0.5 mm from the capillary. The resulting
degradation correction factor was used throughout for simulating CaCO3 degradation. The radius
of the capillary (rc) was set at 10 𝝁m. The partition coefficient (k) of the capillary is dependent on
the capillary pore radius, estimated at 500 nm and particle radius, defined as 100 nm. The initial
concentration of CaCO3 (Cd) in the capillary was estimated as 5% of the infused concentration (set
as 1 mg in a 20 g mouse).
Rpmax was empirically determined as the point at which the average pH in the tissue was 6.65,
identified as 0.0225 M/s. The diffusion coefficient (Dp) was estimated as the diffusion of a particle
with a molecular weight of 1 Da in an extracellular matrix. We used the following constants for
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the simulation based on literature values or model assumptions: r = 50 nm, Ka1 = 4.45*10-7, Ka2 =
4.69*10-11, Ksp = 6*10-9, M = 100.0869 g/mol, 𝜌 = 2.71 g/mL.
3.2.1.1 Modeling IV Injection
The derivation of the above equations are as follows. In general, we can assume that under
ideal conditions the CaCO3 particles are injected via intravenous infusion, allowing for a constant
stable concentration within the blood. The particles can also be assumed to not enter cells due to
the lack of any targeting motifs. We can assume that the liver, spleen, and kidney, remove
approximately 95% of CaCO3 dose, as suggested by radioactive Cu64 experiments. As such, we
make the assumption that the dose of CaCO3 at the tumor site is:
(7) 𝐶𝑏 = 0.05𝐶𝑖𝑛𝑓𝑢𝑠𝑒𝑑
As the particles enter the tumor, we can look at the tumor vasculature model as a parallel
1

combination of tissue cylinders, each composed of a cylinder of length z, radius 𝑟𝑐 = 2 𝑑𝑐 , and a
pore size of 𝑟𝑝 . The particles themselves should not have changed significantly, based on TEM
images of serum incubation, and as such should retain their initial diameter a. Each capillary
supplies a tissue area of radius 𝑟𝑡 which marks the boundary of that tissue cylinder. Because the
tumors are poorly perfused, we can also make the assumption that the tissue cylinder has negligible
contributions to it from other capillaries. (Figure 3.1)
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Figure 3.1: Visualization of the tumor tissue cylinder. Blue cylinder represents a blood vessel of
diameter d, in a tissue cylinder of rt. A tumor volume is simulated as a sum of these cylinders
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3.2.1.2 Modeling Pre-Injection pH gradient
The pH at r= 𝑟𝑐 is maintained at a pH of 7.4. However within the tumor tissue, there is some
rate of proton production 𝑅𝑝𝑚𝑎𝑥 that is a function of pH. We assume there is no convection of
𝑑

𝑑

protons, no contribution from 𝑑𝜃, and 𝑑𝑧, and the system is at steady state. We can also make the
assumption that the system is smooth, and as such, @𝑟 = 𝑟𝑐

𝑑[𝐻 + ]
𝑑𝑟

= 0. As such, we can derive

the distribution of protons in the tumor tissue from the equations.

(8) 0 = −

(9) [𝐻 + ] =

1𝑑
𝑑[𝐻 + ]
(𝑟𝐷𝑝
) + 𝑅𝑝𝑚𝑎𝑥
𝑟 𝑑𝑟
𝑑𝑟

𝑅𝑝𝑚𝑎𝑥 2
𝑅𝑝𝑚𝑎𝑥 𝑟𝑐2
(𝑟 − 𝑟𝑐2 ) +
𝑙𝑛|𝑟𝑐 /𝑟| + 10−7.4
4𝐷
2𝐷
(10) 𝐷 = 1.013 ∗ 10−4 ∗ 1−.46

We assume: 𝑅𝑝𝑚𝑎𝑥 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 = 0.0225 empirically identified as the point that makes the
average pH=~6.8
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The resulting proton gradient in the tissue can be seen in Figure 3.2.
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Figure 3.2: pH gradient in a tumor. The blue circle represents the capillary area. The tissue
cylinder is approximated in the figure as being 100 𝜇m large.
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3.2.1.3 Modeling CaCO3 Diffusion in the Tumor
The capillary also contains pores that range in size from 100 to 500 nm depending on tumor type.
For the purpose of this simulation, we can assume the pore size is 𝑟𝑝 = 500 nm. This results in a
partition coefficient:

(11)

𝑎 2

𝑘 = (1 − 𝑟 )

The concentration of CaCO3 immediately outside of the capillary then can be calculated as:
(12)

𝐶𝑡 = 𝑘 ∗ 𝐶𝑏 = 0.05 ∗ 𝑘 ∗ 𝐶𝑖𝑛𝑓𝑢𝑠𝑒𝑑

The tumor tissue consumes this CaCO3 at a rate 𝑅𝑐𝑚𝑎𝑥 . We can assume, similar to the proton
𝑑

𝑑

gradient that there is no convection of CaCO3, no contribution from 𝑑𝜃, and 𝑑𝑧, and the system is
at steady state. We can also make the assumption that the system is smooth, and as such, @𝑟 =
𝑟𝑐

𝑑[𝐶𝑎𝐶𝑂3 ]
𝑑𝑟

= 0. As such, we can derive the distribution of CaCO3 in the tumor tissue from the

formula:
1 𝑑

(13)

0 = − 𝑟 𝑑𝑟 (𝑟𝐷𝑝

(14)

[𝐶𝑎𝐶𝑂3 ] =

𝑑[𝐶𝑎𝐶𝑂3 ]

𝑅𝑐𝑚𝑎𝑥
4𝐷

𝑑𝑟

) − 𝑅𝑐𝑚𝑎𝑥

(𝑟𝑐2 − 𝑟 2 ) +

𝑅𝑐𝑚𝑎𝑥 𝑟𝑐2
2𝐷

𝑟

𝑙𝑛 |𝑟 | + 𝑘 ∗ 𝐶𝑏
𝑐

To calculate the diffusion coefficient through the interstitial fluid we can use the following
equations. The diffusion of CaCO3 in plasma :
(15)
(16)

𝑘 𝑇

𝐵
𝐷𝑝𝑙𝑎𝑠𝑚𝑎 = 6𝜋𝜇𝑅
; T= 37C, kB=, 𝜇, 𝑅 = 50 ∗ 10−9 𝑚

𝐷𝑚
𝐷

𝑎 2

𝑎 3

𝑎

𝑎 5

= (1 − 𝑟 ) [1 − 2.1 ( 𝑟 ) + 2.09 ( 𝑟 ) − 0.95 ( 𝑟 ) ] (Renkin’s equation)
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Make the assumption that Dm =Dif (diffusion in the interstitium for the nanoparticle). Using
Maxwell’s equation, we can solve for Dt- diffusion coefficient in tissue.
(17)
(18)
(19)

𝐷𝑇
𝐷𝐼𝐹
𝐷𝑇
𝐷𝐼𝐹

=

2𝐷𝐼𝐹 +𝐷𝐶𝑒𝑙𝑙 −2𝜙(𝐷𝐼𝐹 −𝐷𝐶𝑒𝑙𝑙 )
2𝐷𝐼𝐹 +𝐷𝐶𝐸𝑙𝑙 +𝜙(𝐷𝐼𝐹 −𝐷𝐶𝑒𝑙𝑙 )

=

2𝐷𝐼𝐹 −2𝜙(𝐷𝐼𝐹 )
2𝐷𝐼𝐹 +𝜙(𝐷𝐼𝐹 )

𝐷𝑇 =

; For CaCO3 Dcell = 0;

; assume 𝜙 = 0.7, cell fraction of volume

2𝐷𝐼𝐹 −2𝜙(𝐷𝐼𝐹 )
𝐷
2𝐷𝐼𝐹 +𝜙(𝐷𝐼𝐹 ) 𝐼𝐹

3.2.1.4 Calculating degradation of CaCO3 (Rcmax) as a function of pH
Rcmax, however is not constant, but is instead a function of pH, with increased
degradation at lower pHs. CaCO3 dissolution can be determined as a function of pH using the
following formulas.
(20)

CaCO3 dissolution is mediated by the following three equations.
𝐶𝑎𝐶𝑂3 (𝑠) < − > 𝐶𝑎2+ + 𝐶𝑂32−
𝐻2 𝑂 + 𝐻𝐶𝑂3− < − > 𝐻3 𝑂+ + 𝐶𝑂32−
𝐻2 𝑂 + 𝐻2 𝐶𝑂3 < − > 𝐻3 𝑂+ + 𝐻𝐶𝑂3−

Using standard reaction rate equations one can determine the solubility of CaCO3 in a biological
medium as a function of pH.

(21)

𝐶𝑏 = √

𝐾𝑠𝑝
𝐾𝑎1 ∗𝐾𝑎2
((10−𝑝𝐻 )2 +𝐾𝑎1 10−𝑝𝐻 +𝐾𝑎1 𝐾𝑎2 )

The change in radius in each particle can be determined as:
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(22)

𝜕𝑟
𝜕𝑡

=

𝐷𝐶𝑎𝐶𝑂3
𝑎𝜌

(𝐶𝑠 − 𝐶𝑏 )

The change in pH then at any point can be further determined as:
(23)

𝜕𝑝𝐻
𝜕𝑡

=

𝐷
𝑎

𝑎

𝑁

4

4

𝑎

1

∗ 4𝜋(2)2 ∗ (𝐶𝑠 − 𝐶𝑏 ) ∗ 𝑀 ∗ (3 𝜋𝑑 3 − 3 𝜋(2)3 ) ∗ 𝐵

The rate of degradation then Rcmax =
(24)

𝑅𝑐𝑚𝑎𝑥 = −𝐷 ∗ (𝐶𝑠 − 𝐶𝑏 )

To simplify the simulation, assume that Rcmax is average across all of the space based on the
average pH in the tumor volume. If so, we can calculate Rcmax under the conditions at t=0, to
calculate the initial distribution of CaCO3. We assume that CaCO3 does not change size
significantly in aggregate during diffusion through the matrix while being consumed.
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3.2.1.5 Modeling change in pH over time
As the CaCO3 is consumed in each space point, the CaCO3 changes as does the pH. This can then
be iteratively solved per point.
pH changes are equal to:
(25)

𝜕𝑝𝐻
𝜕𝑡

1

= 𝐷 ∗ (𝐶𝑠 − 𝐶𝑏 ) ∗ 𝑑𝑉 ∗ 𝐵 (1/s)

(26)

𝑝𝐻(𝑥, 𝑦) = 𝑝𝐻(𝑥, 𝑦) + 𝑑𝑝𝐻 ∗ 𝑑𝑡

(27)

pH(x,y) = -log (10−𝑝𝐻 + Rpmax*Area);

CaCO3 changes are equal to:

(28)

(29)
(30)

𝐶𝑏 = √
𝜕𝐶
𝜕𝑡

𝐾𝑠𝑝
𝐾𝑎1 ∗𝐾𝑎2
((10−𝑝𝐻 )2 +𝐾𝑎1 10−𝑝𝐻 +𝐾𝑎1 𝐾𝑎2 )

= 𝑅𝑐𝑚𝑎𝑥 = −𝐷 ∗ (𝐶𝑠 − 𝐶𝑏 )

𝐶𝐶𝑎𝐶𝑂3 = 𝐶𝐶𝑎𝐶𝑂3 − 𝑅𝑐𝑚𝑎𝑥 ∗ 𝑑𝑡 ∗ 𝐴𝑟𝑒𝑎
i. When 𝐶𝐶𝑎𝐶𝑂3 =0; iteration stops for that point
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In aggregate, when simulated, the pH appears as visualized in Figure 3.3.

Figure 3.3: Simulated over time, this figure demonstrates the increase in pH around a capillary due
to CaCO3. To see the whole change, the tumor is approximately 1 mm x 1 mm. Scales are kept
constant from 6.5 to 7.4 (pH), and 0 to 1 𝜇M (CaCO3 distribution)
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3.3 Results
3.3.1 Simulation of CaCO3 nanoparticle dissolution in vivo predicts
asymptotic pH increase and buffering to pH 7.4
CaCO3 is an important biomaterial that is widely available in different forms. Although
CaCO3 solutions can serve as buffering agents, a saturated aqueous solution of this salt has
a predicted pKa of about 9, suggesting the potential to induce metabolic alkalosis in vivo.
In the solid state, CaCO3 exists predominantly as calcite, aragonite, or vaterite polymorphs.
Each of these polymorphs differ in their crystal lattice structure. Unlike calcite and
aragonite, which are not soluble in aqueous medium, vaterite is more soluble because of its
low thermodynamic stability compared to the other polymorphs found in nature. For our
intended application, slow but consistent dissolution in mildly acidic solutions is an
essential criterion for a regenerative pHe buffering agent. To prevent metabolic alkalosis
in surrounding healthy tissue, the preferred material should only increase the pH to about
7.4 (normal body pH).
Because CaCO3 dissolution is regulated by basic rate equations, a simulation of its
dissolution and prediction of the expected pH changes in vivo and in vitro is possible
(Figure 3.4). Dissolution of CaCO3 under mildly acidic conditions follows several steps:

𝐶𝑎𝐶𝑂3 (𝑠) ⇋ 𝐶𝑎2+ + 𝐶𝑂32−

(𝐾𝑎1 = 4.45 ∗ 10−7 )

𝐻2 𝑂 + 𝐻𝐶𝑂3− ⇋ 𝐻3 𝑂 + + 𝐶𝑂32− (𝐾𝑎2 = 4.69 ∗ 10−11 )
𝐻2 𝑂 + 𝐻2 𝐶𝑂3 ⇋ 𝐻3 𝑂 + + 𝐻𝐶𝑂3−

(31a)
(31b)
(31c)
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Generation of carbonate in equation (31) drives CaCO3 dissolution under acidic pH
conditions following L’Chatelier’s principle. Previous studies have modeled the pH
changes in response to CaCO3 dissolution in aqueous medium.24 Adapting this model to a
tissue cylinder approach (Figure 3.4a), we derived the following equations:

Cb = √

𝐾𝑠𝑝
𝐾𝑎1 ∗𝐾𝑎2
((10−𝑝𝐻 )2 +𝐾𝑎1 10−𝑝𝐻 +𝐾𝑎1 𝐾𝑎2 )

𝑑𝐶

𝐽 = −𝐷 𝑑𝑥 →
𝑑𝑝𝐻
𝑑𝑡

=−

𝜕𝐶
𝜕𝑡

𝐷 (𝐶𝑠 −𝐶𝑏 )
𝐵

𝑑

𝐴

= 𝑉𝐷
∗

(𝐶𝑠 −𝐶𝑏 )
𝑑

→

𝜕𝑚
𝜕𝑡

(32)

= 𝐴𝐷

(𝐶𝑠 −𝐶𝑏 )
𝑑

1

→

𝜕𝑟𝑝
𝜕𝑡

=

𝐷 (𝐶𝑠 −𝐶𝑏 )
𝜌

𝑑

(33)

(34)

𝐿
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Fig. 3.4 Simulation of CaCO3 dissolution in vivo predicts tumor pHe will increase only to 7.4. (a)
Tissue can be simulated as a series of cylindrical capillaries each supplying a larger cylindrical
volume of tissue. (b) Rate of change in size of CaCO3 particle reaches an equilibrium at pH = 7.4
under in vivo conditions. (c) The distribution of 100 nm CaCO3 nanoparticles in a circular cross
section is simulated to reach ~0.5 mm away from the capillary with constant infusion and degrades
minimally over 60 minutes. (d) Spatial pH distribution over time increases from 6.5 to 7.4 by 60
minutes, and remains at 7.4 for at least 24 h. Capillary source is represented by blue circle in both
(c) and (d).
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The solubility of CaCO3 (Cb) is a function of the solubility product (Ksp), pH, and the
equilibrium constants (Ka1 and Ka2). Change in concentration of CaCO3 is a function of the
CaCO3 concentration (Cs), the solubility (Cb), the surface area (A), the diffusion distance
(d), and volume (V). The radius of the particle (rp) is additionally dependent on the density
of CaCO3 (𝜌). The change in pH is also dependent on the buffering constant, and
approximates A/V as 1/L, where L is the length of the tissue cylinder. Using equations (3234), an equilibration point occurs for dissolving CaCO3 at a pH of 7.4 (Figure 1b). This
suggests that CaCO3 will only increase pH in acidic environments such as those found in
the pHe of solid tumors and that this process is unlikely to induce metabolic alkalosis
because the pH will not exceed 7.4.
To visualize this process in a 3D model, we modeled nano-CaCO3 diffusion in a tissue
matrix using a tissue cylinder model (Figure 1a), where a single capillary is assumed to
feed a tissue cylinder. From this model, we derived the equation for the distribution of
CaCO3 in the tissue cylinder as a function of the radius (r), capillary radius (r c), diffusion
coefficient of CaCO3 (Dc), the partition coefficient (k), degradation rate (R cmax), and the
influx dose (Cd) as follows:

[𝐶𝑎𝐶𝑂3 ] =

𝑅𝑐𝑚𝑎𝑥 2
𝑅𝑐𝑚𝑎𝑥 𝑟𝑐2
𝑟
(𝑟𝑐 − 𝑟 2 ) +
ln | | + 𝑘 ∗ 𝐶𝑑
4𝐷𝑐
2𝐷𝑐
𝑟𝑐
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(35)

The diffusion coefficient (Dc) of the particle in tissue, which is dependent on particle size,
was estimated using the Renkin equation.25 We also derived the initial pH distribution from
diffusion of protons from the capillary to be the following as a function of the rate of proton
production (Rpmax), diffusion of the proton (Dp), radius (r), and capillary radius (rc):

[𝐻 + ] =

𝑅𝑝𝑚𝑎𝑥 2
𝑅𝑝𝑚𝑎𝑥 𝑟𝑐2
𝑟𝑐
(𝑟 − 𝑟𝑐2 ) +
ln | | + 10−7.4
4𝐷𝑝
2𝐷𝑝
𝑟

(36)

The change in proton concentration is thus determined by numerically solving equations
(32), (34), and (36) by iteration. Similarly, CaCO3 concentrations can be calculated by
using a combination of equations (32), (33), and (35) over the associated tissue cylinder.
We find that the CaCO3 concentrations are relatively constant over time, predicting a
particularly slow dissolution process (Figure 3.4c). In addition, the simulation predicts that
the pH does not exceed its maximum of 7.4 by 24 h (Figure 1d). This profile predicts that
in vivo CaCO3 dissolution is acid selective and therefore is an ideal nanomaterial for
modulating the acidic pHe of solid tumors.
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3.4 Discussion
We find several interesting observations with regards to the simulation. One is that the
simulation predicts a halt in pH increase at pH=7.4. This is ideal for the proposed acid
sensitivity of CaCO3 to tumors. However, it goes one step further than seen in the literature by
suggesting that the mechanism of CaCO3 equilibration is due to a reaction rate equilibrium.
Simulations using the transport phenomena present two independent observations. 1) The CaCO3
distribution area, based on the assumptions above, from one capillary is quite large, extending to
almost 1 mm3. This may be due to an over estimation of the interstitial pore size, or may be real.
2) Previous simulations had suggested a very rapid pH modulation, on a nanosecond time scale.
With the distribution simulation, this appears to occur on the order of seconds to minutes,
reflecting pH data that we have seen during in vivo experiments.
The primary limitation is the assumption of 𝑅𝑐𝑚𝑎𝑥 and solubility of CaCO3 in the area based
on the average pH in the area as opposed to a value for every point. Future simulations may take
into account these aspects. In doing so, a more accurate simulation may be able to found,
particularly during the full degradation phase. The model also currently lacks the ability to take
into account that the concentration in blood is not constant during IV injection, but generally a
bolus. To account for this, one can use the formula:
(37)

𝐶 = 𝐶𝑜 𝑒 −𝑘𝑒𝑓𝑓 ∗𝑡 , where 𝑘𝑒𝑓𝑓 is the clearance rate.

However, for the CaCO3, clearance rate is unknown, and as such poorly simulated. That may be
able to be tackled with data from further studies.
We also assume that the CaCO3 dissolution during the initial distribution phase has
negligible impact on CaCO3 radius. Based on the simulation parameters demonstrating that
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changes in CaCO3 distribution take a significant amount of time, this concept may be true.
However, simulating the initial distribution phase of the CaCO3 may be useful.
In addition, for dosing purposes, the simulations suggest that a larger amount of CaCO3 is
necessary at the beginning during the pH increase phase than at the point of stability. This
implies that a bolus dose followed by a continuous low does infusion would be the ideal dosing
range to maintain a normal physiological pH. It also implies that failure to maintain the CaCO3
dosage high enough would result in a return to acidity. Compliance thus will be of large
importance.
Finally, the escape of CaCO3 after CaCO3 in the blood stream and/or lymphatics after its
disappearance has not been explored. In this simulation, we assume that for time t>0, there are
no major changes in the CaCO3 distribution in the tumor. However, particles may continue to
diffuse differently throughout the tissue as dissolution reduce their individual diameters.
Alternatively, they may also return to the blood stream over time, particularly with concentration
in the blood stream dropping to close to zero. Accounting for these kinetics would add greatly to
the robust nature of the model.
Nevertheless, in conclusion, the current model allows for the testing and understanding of
multiple aspects, including 1) the distribution of CaCO3 in tissue as a function of particle size and
pore sizes, and 2) the subsequent effects on pH over time. This model provides the ability to
predict pH changes in the tumor that would otherwise not be possible.
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Chapter 4.
Synthesis and Stabilization of pH Modulating
Nanoparticles

79

Chapter Summary
Nano-CaCO3 crystals show promise to demonstrate impact on tumor growth as both a
therapy and as a vehicle, but are not widely adopted due to high batch to batch variability during
traditional water based synthesis due to spontaneous crystal growth. CaCO3 crystals have a stable
size of approximately 1-2 microns post grinding. The knowledge on how to create and stabilize
the formation of nano-scale CaCO3 is lacking. In this study, we discover a novel reproducible
vacuum assisted CaCO3 nanocrystal synthesis that increase yield, reduce size, and reduce
aggregation. We find that the mechanism of action of synthesis is dependent primarily on the
aerosolization of ammonium bicarbonate, with the reproducible size constrained phenomenon
primarily due to the nano-crystalline form of ammonium bicarbonate. In this chapter we identify
the critical fundamental variables for making this particularly robust technique more widely used
for nano-CaCO3 synthesis. Further, we demonstrate the ability for this method to produce other
metal carbonate nanocrystals of gold, iron, and zinc carbonate. Finally, we demonstrate the
stabilization of nano-CaCO3 using albumin to allow for in vivo injection.
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4.1 Introduction
Nano-CaCO3 has had a growing interest in a number of applications in tumor therapy as a
platform for drug delivery, and its mechanism of synthesis has broader interest in a wide number
of fields including geology and bone mineral biology. 1-8 Although a number of groups have
attempted to produce CaCO3 nanoparticles, the majority have been developed in water, and
nano-CaCO3 water based synthesis is generally not reproducible from batch to batch.3,9-11 This is
due to the rapid crystal growth of CaCO3 when synthesized in water that can make it hard to
control crystal type and size.12,13
Recently, a gas diffusion anhydrous ethanol assisted method, using CaCl2 dihydrate, was
utilized to produce 100 nm amorphous CaCO3 to avoid the crystal growth from water during
synthesis.14 However, the amorphous particles changed crystallinity and grew when added to
aqueous solutions, which is a potential problem during injection into in vivo systems.
In this chapter we describe the synthesis of nano CaCO3 crystals of the vaterite form using
two different techniques that build on the both water and ethanol based synthetic techniques.
There is little known about the mechanism of these techniques, such as what variables control
size, yield, and distribution. In order to make this method practical, we explore a step by step
analysis of the method by investigating variables such as solvent type, concentration and mass of
starting reagents, duration of synthesis, and combinations of volume and surface area.
For the gas diffusion method, counterintuitively, we find that the concentration, volume, and
surface area of CaCl2 have no effect on size. Instead, we discover that only the number of runs
using the same batch of ammonium bicarbonate and the amount of ammonium bicarbonate
controls size. TEM analysis of ammonium bicarbonate reveals nanocrystalline precursors whose
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size follows the above observations and explain the reproducibility. Time, volume, and amount
of reagents can change yield. This also allows a wider range of solvents to be used than simply
EtOH. We observed that this phenomenon can be found in other organic solvents such as MeOH
and DMF, but breaks down in the presence of substantial amounts of water. We also demonstrate
that this synthesis technique can be extended to gold, iron, or zinc carbonate crystals.
Based on these observations, we posit a model for the synthesis mechanism based on the
aerosolization of ammonium bicarbonate nanocrystals, with larger nanocrystals being
aerosolized and deposited first, and smaller ones being deposited later. As such, size, and yield
can be controlled by the number of runs or amount of ammonium bicarbonate. This knowledge
allows the possibility of scaling up production of Nano CaCO3 with significant reproducibility.
This is crucial for being able to use CaCO3 as a platform nanotechnology similar to gold or silver
nanoparticles. Controlling size is critical for these studies to maximize the enhanced permeation
and retention effect necessary for the accumulation of nanoparticles in tumors.15 For instance, in
the case of CaCO3, we and others have demonstrated that 100 nm CaCO3 has can neutralize
extracellular acidic pH.1-3,16 Smaller CaCO3 particles could even be used to enter the intracellular
space.
Stabilizing CaCO3 in aqueous solutions remains a challenge. To tackle this question we
evaluate a number of different solvents and their effect on CaCO3 crystallinity and size over
time. We discover that albumin is capable of maintaining particle size in aqueous solution,
allowing further stability and in vivo applications.
By systematically evaluating variables involved in vacuum assisted CaCO3 nanoparticle
synthesis we have identified a model to design and produce a reproducible set of CaCO3 particles
of various sizes and yields. In the process, we have characterized a uniquely robust method of
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nanoparticle synthesis that is based on the aerosolization of a reagent under vacuum, in this case
ammonium bicarbonate. By identifying albumin as a stabilizing medium, we open up nanoCaCO3 for in vivo applications.
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4.2 Materials and Methods
4.2.1 Synthesis of 100 nm nano-CaCO3
We synthesized 100 nm CaCO3 nanoparticles using a gas diffusion method. CaCl2*6H2O (220
mg) was dissolved by vortexing in anhydrous ethanol (50 mL). The resulting solution was
transferred to a 100 mL beaker covered with parafilm. After puncturing small holes in the parafilm,
the beaker was placed in a desiccator (with drierite) surrounded by four 20 mL vials containing
excess dry ammonium bicarbonate (~9-10 g). The entire system was placed under vacuum for 25
h. The particles were centrifuged at 6800 g for 10 min, excess ethanol decanted, and the residue
was left to dry in open air before use.

4.2.2 Synthesis of 20 and 300 nm CaCO3.
A double decomposition reaction was used to prepare the CaCO3 particles by mixing 0.1 M each
of CaCl2*2H2O and NaHCO3 at room temperature. The premix solutions of CaCl2*2H2O and
NaHCO3 were prepared in water and polyethylene glycol (1:5 v/v; average molecular weight 1450
Da) for ~20 nm, and water and ethylene glycol (1:5 v/v; molecular weight 62.07 g/mol) for ~300
nm particles. The synthesized CaCO3 particles were collected by sequentially washing the product
with ethanol, methanol and acetone, followed by drying at 60 °C for 1 h. (Figure 4.1)

4.2.3 Modified Synthesis of CaCO3
CaCl2 Hexahydrate (Sigma Aldrich) was dissolved in a volume of anhydrous ethanol as
described above, and placed in a 400 mL beaker in a dessicator (with drierite), surrounded by 20
mL glass vials filled with ammonium bicarbonate of a controlled mass (typically 20 g per vial)
and placed under vacuum for 1- 3 days. The specific days, volume, mass, or surface area are as
described below. (Figure 4.1)
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Figure 4.1. Synthesis and Experimental Schema for nano-CaCO3 synthesis. (a) Synthesis
schema for the gas diffusion method for nano-CaCO3 synthesis. (b) Synthesis schema for
synthesis of nano-CaCO3 using sol-gel. Both methods can be used to make 20 nm, 100 nm, and
300 nm particles. Synthesis was followed by suspension in an aqueous solvent followed by in
vivo experiments in murine models.
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4.2.7 Synthesis of AuCO3, ZnCO3, FeCO3
140-200 mg of AuCl3, FeCl3, and ZnCl2 (Sigma Aldrich) was dissolved in 50 mL of anhydrous
ethanol as described below, and placed in a 400 mL beaker in a desiccator (with drierite),
surrounded by 20 mL glass vials filled with ammonium bicarbonate of a controlled mass
(typically 20 g per vial) and placed under vacuum for 2 days.

4.2.8 Transmission Electron Microscope (TEM).
TEM micrographs were obtained using a FEI Spirit TEM (Hillsboro, USA) operated at 120 kV.
A 400-mesh Formvar® carbon-coated copper grid was glow-discharged in a vacuum evaporator
(Denton, Moorestown, New Jersey) for 30 s. The sample was prepared by placing 2 μL of
sonicated CaCO3 nanoparticles solution onto the grid and wicking off the excess sample with filter
paper after 30 s. Alternatively, for EtOH or DMSO solvent based solutions, 3 𝝁L of particle
solution were placed on the grid and left to dry out at room temperature or with the aid of a heat
gun.

4.2.9 X-Ray Diffraction (XRD).
XRD patterns were obtained by using the Bruker d8 Advance X-ray Diffractometer (Bruker,
USA) configured with a Cu X-Ray tube with 1.5418 Å for analysis of powder samples using
LYNXEYE_XE detector. For the analysis, fine acetone ground CaCO3 nanoparticles were kept
on a Zero Diffraction Plate (MTI Corporation, USA). XRD data were scanned from 20-60
degrees, with a 0.04 degree step size, a 0.5 s per step count time, with sample rotation turned on
(15 rotations per min), with a coupled two-theta/theta scan. The Bruker Diffrac.Eva program was
used for the evaluation and processing of X-ray diffraction scan data. Search-match operations
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included search by DI list, by name, using chemistry filters, and creating an International Centre
for Diffraction Data (ICCDD PDF) database filter.

4.2.10 Hydrodynamic diameter and electro-kinetic zeta potential.
To study agglomeration kinetics of CaCO3 nanoparticles, hydrodynamic diameter (Dh) was
measured using DLS (Malvern Instruments, Southborough, Massachusetts). Agglomeration
kinetics were measured on the basis of data obtained from TR-DLS.
The zeta potential was measured using a Malvern Zetasizer Nano ZS instrument. An applied
voltage of 100 V was used for the nanoparticles. A minimum of three measurements were made
per sample.

4.2.11 Identification of stable aqueous medium for nano-CaCO3.
Nano-CaCO3 was resuspended in the following solvents: (1) dIH 2O; (2) Dulbecco’s PBS,
(3) PBS, 1 mM CaCl2, and 1 mM MgCl2 ; (4) PBS, CaCl2, MgCl2 and 2% bovine serum
albumin; (5) fetal bovine serum (FBS); and (6) a solution consisting of 20% (PBS, CaCl 2,
MgCl2, and 2% bovine serum albumin) in 80% FBS. The results of particle stability were
analyzed by TR-DLS for up to 7 h, TEM under aqueous conditions, TEM under serum, and
XRD after 7 h.

4.2.12 Yield measurement
Yield was determined by centrifuging 10 mL of particle ethanol solution at 6800 x g for 10
minutes into Eppendorf tubes and air dried. Mass was measured before and after of the tube,
giving the concentration per 10 mL which was multiplied by the volume of solution remaining.
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4.3 Results
4.3.1 Independent facile synthetic methods produce pure vaterite
nanoparticles with controlled size range from 20 – 300 nm
The malformation of blood and drainage vessels around solid tumors creates an
environment for the selective retention of nanoparticles through the enhanced permeation
and retention (EPR) effect.15 Typically, materials with core diameters less than 500 nm are
preferred to enhance intravascular dynamics and diffusion to tumor cells further from the
blood vessels.15,17
Unfortunately, CaCO3 nanoparticles that are stable in aqueous solutions have been
difficult to synthesize at sub-micron sizes without the use of harsh conditions (custom high
pressure systems), doping materials (lipid-based surfactants), other additives such as
phosphate, polystyrene, and drugs, or a combination of calcium phosphate and calcium
carbonate.1,2,4,7,18 Attempts to prepare pure nano-CaCO3 have generally resulted in the
production of materials with core diameter > 500 nm3,5,9 due to difficulty in controlling the
particle’s growth. Furthermore, CaCO3 nanoparticles can rapidly grow to larger crystalline
polymorphs (calcite, vaterite, or aragonite) when placed under aqueous conditions via a
variety of mechanisms.8,12-14,19
Building on literature methods, we have identified two independent methods to produce
pristine sub-micron vaterite nano-CaCO3 with distinct size ranges at 20 nm, 100 nm, and
300 nm. Synthesis of the 100 nm nano-CaCO3 was accomplished by using a gas diffusion
method (Figure 4.1, Methods section).14 The stepwise approach of exposing calcium
chloride in anhydrous ethanol to controlled amounts of ammonium bicarbonate, followed
88

by gradual air drying of the product, afforded a simple and highly reproducible method to
prepare these nanoparticles. To provide flexibility in particle size, we used a double
decomposition reaction method between hydrated calcium chloride and sodium bicarbonate
at room temperature. Size control was achieved by mixing the reactants in a mixture of
solvents consisting of 1:5 ratio of water/polyethylene glycol (20 nm) and water/ethylene
glycol (300 nm). The ethylene glycol and polyethylene glycol were used to modulate the
diffusion rate of calcium and carbonate ions, thereby controlling nucleation and growth by
particle cluster formation.20,21 This approach revealed that solvent viscosity can serve as a
modular strategy to prepare pure vaterite nanoparticles.
The size and morphology of synthesized nano-CaCO3 were determined by transmission
electron microscopy (TEM) and dynamic light scattering (DLS) (Figure 4.2). Typical TEM
micrographs revealed that nano-CaCO3 were primarily spherical, as expected for vaterite.
The geometric mean diameters of the nano-CaCO3 were 20 ± 1.4 nm, 100 ± 8.3 nm and
300 ± 14.6 nm (Figure 4.2a-c). Expectedly, DLS revealed a slight increase in the
hydrodynamic diameter (Dh) for all particle sizes because of the interaction of solvent
molecules with the surface of particles, creating a thin layer of solvent molecules (Figure
2d).
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Fig. 4.2 Independent facile synthesis methods can produce nano-CaCO3 at various sizes.
(a) TEM of 20 nm vaterite demonstrates rod like particles with a tendency for aggregation.
(b) TEM of 100 nm vaterite shows spherical particles. (c) TEM for 300 nm vaterite
demonstrates larger spherical particles. (d) DLS results in ethanol for the 3 particle sizes
replicates TEM findings. (e) XRD of 100 nm CaCO3 demonstrates vaterite signature.
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However, two peaks were observed in the DLS profile of the 20 nm nanoparticles, in
which one peak exhibited smaller Dh than the physical diameter. These peaks could arise
from the asymmetric shape of the particles, as shown in the 20 nm particles (Figure 4.2a).22
Larger sizes were typically spherical, accounting for the lack of a second smaller peak.
Irrespective of the synthesis method, all three sizes of the nano-CaCO3 showed peaks at
theta angles of 24.8, 27.1, 32.8 and 43.9, which are consistent with the characteristic
hexagonal vaterite crystalline structure of CaCO3 (Figure 4.2e & Figure 4.3). Because
vaterite is more soluble in aqueous media than other CaCO3 polymorphs, these materials
are suitable for use in neutralizing the acidic pHe of tumors if they can remain stable in
aqueous environments without rapidly converting to the less soluble calcite.
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Figure 4.3. X-Ray diffraction post addition of albumin based solvent shows stability in all three sizes of
particles. (a) XRD of 20 nm nano-CaCO3 is identical in EtOH and in 2% albumin + PBS + CaCl2 + MgCl2
solution. (b) XRD of 100 nm nano-CaCO3 is identical in EtOH and in 2% albumin + PBS + CaCl2 +
MgCl2 solution. (c) XRD of 200 nm nano-CaCO3 is identical in EtOH and in 2% albumin + PBS + CaCl2
+ MgCl2 solution. All plots, when compared to literature, match the structure of vaterite.
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4.3.2 Albumin prevents rapid conversion of vaterite nanoparticles to calcite or
calcium phosphate in aqueous medium and serum
The solubility and stability of these vaterite nanoparticles are critical for successful
biological applications in vivo. We explored a variety of biologically compatible media to
identify the optimal storage conditions and vector for intravenous (I.V.) administration of
the nano-CaCO3 (Figure 4.4; Figure 4.5). DLS analysis shows a rapid increase of the 100
nm vaterite nanoparticles from 100 nm to over 500 nm within a few seconds in saline and
in phosphate buffered saline (PBS; Figure 4.4a). The observed morphological change in
PBS could be attributed to calcite or CaPO4 formation. However, addition of 2% albumin
to PBS remarkably stabilized the materials for extended periods, demonstrating the
potential of formulating vaterite nanoparticles in this medium for I.V. administration
(Figure 4.4a,b). A similar trend was observed with the 20 nm and 300 nm nano-CaCO3
(Figure 4.6).
We further determined the long-term particle stability in different media for up to 7 h.
Time-resolved DLS (TR-DLS) suggests that the particles in aqueous albumin containing
solution exist in pairs of 2 or 3 (size 2-3 times larger than in ethanol), which dissociate into
individual particles upon exposure to fetal serum (Figure 4.4a, Figure 4.6). TEM confirmed
the high stability of the particles in albumin solution (Figure 4.4b, Figure 4.6). X-Ray
Diffraction (XRD) analysis did not show any change in crystallinity in albumin-based
aqueous media (Figure 4.4c). The nano-CaCO3 exhibited stability in both morphology and
size in fetal bovine serum (Figure 4,4d, Figure 4.6).
These results suggest that albumin, which has a high affinity for calcium, 23 serves as a
calcium sink that prevents aggregation and calcium phosphate formation in PBS. The
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minimal change in TEM (structural) and X-ray diffraction (crystalline) analyses confirms
that extensive double replacement to form CaPO4 did not occur. In general, clusters of three
nano-CaCO3 form in albumin solutions, which separate into single particle serum is added
to the mixture. The additional serum stability conferred on nano-CaCO3 in aqueous albumin
solution indicates that pre-formulation of the nanoparticles in this medium is ideal for in
vivo application, where serum is abundant.

94

Fig. 4.4 Nano-CaCO3 is stabilized in an albumin based solution. (a) DLS results of 100 nm
particles show that stability in serum > PBS+BSA+CaCl 2 > PBS+CaCl2 > Saline = DI
Water > PBS. (b) TEM shows 100 nm particles in albumin solution have unchanged
morphology surrounded by albumin. (c) XRD of 100 nm particles in albumin solution at
24 h shows no changes in crystalline structure. (d) TEM of particles post serum incubation
demonstrate no change in structure, with particles embedded in serum protein.
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Figure 4.5 CaCO3 grows in size in a variety of solvent incubations for 100 nm nano-CaCO3 except
albumin containing solutions. (a), At synthesis, particles are monodisperse and 100 nm in size. Scale
bar represents 50 nm. (b), When placed into deionized H2O, particles rapidly grow to be > 1 𝜇m.
Scale bar is 1 𝜇m. (c), When 100 nm nano-CaCO3 is placed into 15 mM saline, particles grow to
greater the > 1 𝜇m. Scale is 1 𝜇m. (d), When placed into PBS, particles become cuboidal in shape and
large. Scale bar is 1 𝜇m. (e), Coating particles with a hydrophobic coating using Poly-Vinyl
Pyrrolidone (PVP), slows reaction and makes growth slightly slow. Scale bar is 0.5 𝜇m. (f), Coating
particles with a hydrophobic coating using Poly-2-Vinyl Pyrrolidone (PVP), slows reaction and
makes growth slightly slow. Scale bar is 0.5 𝜇m. (g), Adding CaCl2 and MgCl2 to the PBS solution
slows CaCO3 growth, with some reaction appearing to occur. Scale is 200 nm. (h), Adding 2%
albumin to a solvent of PBS + CaCl2 + MgCl2 preserves particle morphology.
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Figure 4.6. 20 nm and 300 nm particles show stability in albumin containing solution and in
serum. (a) DLS results over time in a variety of aqueous solvents for 20 nm particles
demonstrates that particles on addition to serum separate from an aggregate in 2% albumin. (b),
TEM of 20 nm particles in PBS + CaCl2 + MgCl2 + 2% albumin shows separation . Scale bar is
200 nm. (c), TEM of 20 nm particles post serum incubation shows retention of morphology. (d),
DLS results over time in a variety of aqueous solvents for 300 nm particles show the same trend
as 20 nm and 100 nm particles in solvent stability. (e), 300 nm particles under 2% albumin +
PBS show some slight increase in size. Scale bar for large image is 200 nm. Scale bar for
magnified image is 100 nm. (f), 300 nm particles in serum show retention of shape and
morphology. Scale bar is 200 nm.
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Synthesis of CaCO3 nanoparticles via the vacuum assisted method occurs in a solution of CaCl2
hexahydrate in EtOH placed in a beaker covered by a parafilm with small holes punctured
through (Figure 4.7). Ammonium bicarbonate is placed in small uncapped vials surrounding the
beaker, usually 10 – 20 g of ammonium bicarbonate per vial (Figure 4.7). Both of these reagents
are placed in a dessicator including drierite, and placed under continuous house vacuum for 24 to
48 hours (Figure 4.7).

CaCl2(H2O)
6

NH4HCO
3

(a)
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Figure 4.7. (a) Synthesis contraption. Solid ammonium bicarbonate is placed around CaCl2
hexahydrate over varying periods of time in order to synthesize vaterite based CaCO3
nanoparticles.
We then further determined how to make this synthesis process more efficient by exploring
both the variables and the mechanism behind this method. We considered the following variables
towards identifying efficient CaCO3 synthesis, including time under vacuum, concentration of
CaCl2, volume of solution, exposed surface area of CaCl2 solution, surface area of ammonium
bicarbonate, amount of ammonium bicarbonate, number of runs, and amount of water in the
EtOH solvent. Temperature was held at room temperature, the desiccator size was 11.5” in
diameter, and vacuum pressure was kept at maximum house vacuum.
CaCO3 has a thermodynamic equilibrium point at > 1 𝜇m in aqueous solution. Because
we consistently see 100 nm particles, we focused on kinetic or other constraints on size. In
particular, we hypothesized three possibilities for the mechanism constraining size in particle
formation: one, a nucleation event of CaCO3 that then grows with repeated deposition; two,
CaCl2 hexahydrate forms size constrained small water droplets in the EtOH; or three,
aerosolization of ammonium bicarbonate under vacuum creates size constrained particles.

4.3.3 CaCO3 particles do not grow from repeated layer by layer deposition in
ethanol assisted synthesis.
To test the first hypothesis, we investigated the change in the size of the nanoparticles over
time under synthesis. We hypothesized that CaCO3 deposition could occur by the initial
aerosolizing ammonium bicarbonate to form a nucleating event that then grew with additional
ammonium bicarbonate depositing over time, similar to processes seen in gold or silver
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nanoparticles and in more classical water based synthesis techniques for CaCO3.1,24 In this case,
we expect that each CaCO3 particle itself would grow in size with increasing time under the
reaction. If not true, we would expect that the number of particles would change but not the size,
i.e. changing yield independent of size. We approached this question by testing the yield and size
distribution of CaCO3 after different amounts of time under vacuum.
We find that nano-CaCO3 synthesis occurs very quickly after starting vacuum flow.
However, we found that it took approximately 24 hours to synthesize quantities useful for animal
experiments, and as such we used this time point as an initial baseline. When comparing the
yield at 24 hours versus 72 hours, we find a 10 fold increase in yield (Figure 4.8a). In
comparison, increasing the volume of CaCl2 solutions by four fold only increased the yield by
1.4x (Figure 4.8a). In addition, via TEM, we find that there are no changes in the size of the
particles with the increase in time, suggesting a non-layering synthesis mechanism (comparing
Figure 4.8b and 4.8c). The increase in yield does evidently have a tradeoff with aggregation,
with a larger degree of clumping of individual particles with larger amounts of time, but no
merging of the particles (Figure 4.8c). The lack of crystal fusion in the clumps adds further
evidence against the possibility of a nucleation and growth mechanism.
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Figure 4.8. (a) Yield increases with number of days substantially, and volume by a minor part.
(b) TEM of particles after 24 hours (50 mL volume, 4 mg/mL CaCl2(H2O)6 concentration, 4
vials), scale bar 500 nm. (c) TEM of particles after 38 hours (50 mL volume, 4.4 mg/mL
CaCl2(H2O)6 concentration, 4 vials), scale bar 500 nm.

4.3.4 CaCO3 size is not influenced by the amount or state of CaCl2(H2O)6 in
the EtOH solution
In our second theory, if CaCl2 hexahydrate was to form micellar-like size constrained
droplets in the EtOH solution, we would expect the particle size to be dependent on the
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concentration of CaCl2 hexahydrate or other factors of the solution itself. Micelle size is typically
controlled by the ratio of aqueous to non-aqueous solution and surfactant concentration. We
investigated whether any micellar-like phenomenon was occurring here by varying the
concentration of CaCl2 in solution, the surface area of exposure, and the volume of solution, and
assessing the resulting size of particles via TEM. If true, we would expect that the putative nanodroplets of CaCl2 hexahydrate would be directly related to these factors.
As such, we tested CaCO3 synthesis at different concentrations, volumes and surface areas
of solutions. We find that the concentration of CaCl2 hexahydrate in EtOH does not affect size of
the resulting particles when controlling for surface area and volume (comparing Figure 4.9a and
4.9b). Going further, we tested changing surface area while controlling volume, and we find no
change in average particle size (comparing Figure 4.9c and 4.9d). When we test changes in the
absolute amount by changing volume we also find no change in size (comparing Figure 4.9e and
4.9f). These results conclude that the size of the particle is not restricted by amount or
concentration of the CaCl2 hexahydrate EtOH solution.
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Figure 4.9. CaCl2(H2O)6 solution has no effect on size. (a) TEM of particles made under 4.4
mg/mL CaCl2(H2O)6, with 4 vials ammonium bicarbonate, in 50 mL over 3 days in a 77 mm
diameter beaker, scale bar is 500 nm. (b) TEM of particles made under 16 mg/mL CaCl2(H2O)6
with 4 vials ammonium bicarbonate in 50 mL volume over 3 days in a 77 mm diameter, scale bar
is 1 𝜇m. (c) TEM of particles made in a 4.4 mg/ mL CaCl2(H2O)6 concentration in 50 mL
volume, in a 68 mm diameter flask for 1 day, scale bar is 200 nm. (d) TEM of particles made in
a 2.8 mg/mL CaCl2(H2O)6 concentration in a 50 mL volume with 77 mm diameter over 2 days,
scale bar is 100 nm.(e) Particles made in a 4.4 mg/mL CaCl2(H2O)6 concentration with 4 vials in
68 mm diameter, with 50 mL volume over 1 day, scale bar is 200 nm. (f) 4.4 mg/mL
CaCl2(H2O)6 4 vials 77 mm diameter in 223 mL volume over 3 days, scale bar is 200 nm.
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4.3.5 Synthesis is dependent on the aerosolization of ammonium bicarbonate
for changes in size and yield
Given the above results, we tested the third hypothesis that synthesis is dependent on the
aerosolization process of ammonium bicarbonate under vacuum. The original reports of the
method did not report the amount of ammonium bicarbonate used, and generally kept the amount
in large excess compared to the concentration of CaCl2 hexahydrate. If it is dependent on
ammonium bicarbonate then we would expect that the size would change based on changes in
ammonium bicarbonate, such as amount, age, or number of runs.
Because of the nature of the synthesis reaction, during experimentation, it is possible to
retain the approximately same mass of ammonium bicarbonate experiment after experiment due
to its solid state. In all of the experiments seen in Figure 4.10, the number of vials of ammonium
bicarbonate ~ 20 g per vial remained constant at 15 vials unless noted otherwise. Per
experimental run, we find that size and yield decreases (compare Figure 4.10a to 4.10b and
4.10c, Figure 4.11). We postulate that this effect is due to decreasing amounts of ammonium
bicarbonate aerosolizing and smaller crystals aerosalizing during each experimental run. Indeed,
this effect aligns directly with the age of the ammonium bicarbonate reducing the yield and size
of particles (Figure 4.11a, c, d). Combining an old series of vials with a new vial results in a
mixed batch of particles, including both smaller and larger particles, suggesting particle is based
purely on the ammonium bicarbonate at the solid to gas interface and not forming in transit to the
gas-liquid interface (Figure 4.11b).
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We were able to replicate this effect by reducing the absolute amount of ammonium
bicarbonate below the point of excess. When testing synthesis with a 1:1 or 1:2 ratio of
ammonium bicarbonate and CaCl2 hexahydrate, we find a significantly smaller diameter particle
adding credence to this hypothesis (compare Figure 4d to 4f). However, it is clear that the size
appears to plateau at 100 nm quickly above the 1:1 point.

Figure 4.10. Ammonium bicarbonate has an effect on size (a) TEM images of particles on the
first run of 300 g ammonium bicarbonate over two days, scale bar is 200 nm. (b) TEM images
of particles on the approximately third run, at approximately the same mass of ammonium
bicarbonate over two days, scale bar is 100 nm. (c) TEM images of particles on the
approximately fifth run, at approximately the same mass of ammonium bicarbonate over two
days, scale bar is 100 nm. (d) TEM images of particles on the first run using 127 mg of
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ammonium bicarbonate, over two days, scale bar is 200 nm. (e) TEM images of particles on
the first run using 57 mg of ammonium bicarbonate, over two days, scale bar is 200 nm. (f)
TEM images of particles on the first run using 7.9 mg ammonium bicarbonate, over two days,
scale bar is 200 nm.

Figure 4.11. Particle size and yield is dependent on the age of ammonium bicarbonate. a)
Yield over time via aging of ammonium bicarbonate over runs b) TEM of synthesis using a mix
of new and old NH4CO3, scale bar is 200 nm c) TEM of synthesis using 2 months old NH4CO3,
scale bar is 200 nm, subset, scale bar is 50 nm d) TEM of synthesis using over 6 month old
ammonium bicarbonate, scale bar is 200 nm, subset, scale bar is 50 nm.
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The surface area of ammonium bicarbonate, in general, did not change the size (compare
Figure 4.12a vs 4.12b). However when placing a large amount of ammonium bicarbonate in a
400 mL beaker, a relatively low surface area to mass, we find large fused aggregates /
microparticle formation (Figure 4.12c). Reducing the amount of ammonium bicarbonate or
increasing the surface area was able to correct for the aggregation effect (Figure 4.12b, 4.12d).

Figure 4.12. Particle size is not dependent on surface area of ammonium bicarbonate. a)
TEM of particle synthesis using 30 grams of NH4CO3 in a 100 mL beaker, scale bar 200 nm b)
TEM of particle synthesis using 30 grams of NH4CO3 in a 400 mL beaker, with some particle
clumping noted, scale bar 200 nm c) TEM of particle synthesis using 157 g of NH4CO3 in a 400

107

mL beaker, scale bar 1 𝜇m d) TEM of particle synthesis using approximately 157 g of NH4CO3
spread across 15 vials, scale bar 500 nm.
Given the dependence on NH4CO3 we took TEM of the ammonium bicarbonate samples.
TEM of the ammonium bicarbonate samples fresh and after several runs revealed nanocrystals
that aligned with the above observations. (Figure 4.13a, 4.13b). In particular, in the fresh
ammonium bicarbonate the nanocrystals are closer to the larger 100 nm. (Figure 4.13a) In the
ammonium bicarbonate after several runs we find the nanocrystals are closer to 20 nm
suggesting that the larger ammonium bicarbonate disappeared with runs, and explaining the
lowering size.

Figure 4.13 TEM of Ammonium bicarbonate a) TEM of fresh ammonium bicarbonate pre
reaction, scale bar 500 nm, subset 100 nm b) TEM of ammonium bicarbonate after reaction x3,
scale bar 200 nm
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4.3.6 Ammonium bicarbonate constrained synthesis of CaCO3 can use a
variety of organic solvents
Given the constrained size by ammonium bicarbonate we hypothesized that a similar
synthesis of CaCO3 would occur in other organic solvents. (Figure 4.14). We find that MeOH
has identical particle formation, with a high yield. Synthesis in DMF is curious in that we see a
mix of small and large particles. The synthesis technique does break down in water with large
aggregates forming. We found that small amounts of water (0.4%, 200 𝜇L) can be tolerated
(Figure 4.14a). In particular hypothesize that the formation of vaterite instead of amorphous
CaCO3, as described previously14, is due to the increased water concentration from the
hexahydrate. Larger amounts of water (20%, 10 mL), on the other hand caused a disruption of
the spherical structure and created large aggregates (Figure 4.14b). This may be related to the
capacity of the dessicator to dry out the EtOH + H2O solution.
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Figure 4.14 Ammonium bicarbonate constrained CaCO3 synthesis in other solvents: a)
With 200𝜇L water in 50 mL EtOH b) with 20% water/EtOH c) in DMF d) in MeOH

4.3.7 Ammonium Bicarbonate Constrained Vacuum Assisted Synthesis can be
used to create other carbonate nanoparticles.
We find that applying the same exact synthesis technique albeit with 140 mg to 200 mg of
AuCl2, FeCl2¸or ZnCl2 induces the similar formation of the respective carbonate nanoparticles,
constrained to approximately 100 nm in size. This validates the hypothesis that the size
constraint comes from the ammonium bicarbonate crystals and not the salt-EtOH solution.
(Figure 4.15).
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Figure 4.15 Ammonium bicarbonate constrained metal carbonate synthesis in EtOH. Scale
bar 0.5 μm, subset 100 nm a) AuCO3 b) ZnCO3 c)FeCO

111

4.4. Discussion
CaCO3 suffers from poor replicability and ill-understood synthesis steps. To better
understand CaCO3 nanoparticle formation, we undertook a detailed study on the factors involved
in size determination and yield in a highly reproducible synthesis procedure based on ammonium
bicarbonate aerosolization (Table 4.1).
Table 4.1: Summary of factors and effect on size and yield.
Factor

Size

Yield

Concentration of CaCl2

No Effect

Increase

Volume of CaCl2 solution

No Effect

Increase

Surface area of CaCl2

No Effect

No Effect

Time under vacuum

No Effect

Increase

# of runs

Decreases

Decreases

Amount of ammonium

Increases size to 100 nm

Increases

No effect (to a point)

No Effect

solution

bicarbonate
Surface Area of ammonium
bicarbonate

Aerosolization based nanoparticle synthesis is rare, especially resulting in monodisperse
nano-crystals. Indeed, previous studies have shown that controlling aerosolization is difficult. 25
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As a result, more classical synthesis techniques control size by time-based deposition or
restriction from a micellar nano-bubble form. However, for this synthesis technique we find a
counterintuitive phenomenon, with neither of those effects occurring. Note that the solution is
not being homogenized as there is no stirring involved, and yet the particles are remarkably
monodisperse. This phenomenon adds credence to the dependence of the nanoparticle size on
ammonium bicarbonate nanocrystals.
Thus, vacuum assisted synthesis of CaCO3 reveals a rare method of synthesis of
nanoparticles via aerosolization of a solid reagent, in this case nano-crystal ammonium
bicarbonate. Future work will look at exploring nanoparticle generation in this class of synthesis,
particularly expanding on the ability to produce carbonate nanocrystals of other metals, including
gold, iron and zinc.. The reliance on a relatively small number of variables of only one reagent
makes this synthesis technique particularly robust, explaining its high reproducibility.
Overall, CaCO3 as a nanomaterial has multiple uses in vivo as a drug delivery carrier and
therapeutic. To be used widely, we describe the mechanism behind vacuum assisted CaCO3
synthesis. In this study we demonstrated the only underlying involved in determining the size of
CaCO3 particles was the ammonium bicarbonate nanocrystals. Moreover, because the nanoparticle
size is dependent only on a very limited number of variables during synthesis, we find that the
synthesis method is particularly robust and allows the synthesis for a wide range of nanocrystals.
Controlling the crystal growth of a nanoparticle has continued to be difficult. The identification of
albumin enables the use of CaCO3 in vivo for exploring the therapeutic implications of CaCO3The
extension of the method to other carbonate crystals, as described here for gold, zinc, and iron,
opens a new field for carbonate crystal engineering.
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Chapter 5: Biodistribution and Toxicity Screening of
CaCO3 in vivo
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5.1 Introduction
Cancer therapy remains a difficult problem, with significant side effects and off target effects
of common methods. Nano-CaCO3 may potentially be a useful platform for tumor therapy via
two mechanisms, pH sensitive drug delivery and direct modulation of the local pH. 1-4
Nano-CaCO3 has significantly useful properties over other nanoparticle platforms. The
degradation products of Nano-CaCO3 are only calcium, which is regulated by the kidney and
deposited into the bone and CO2 which is rapidly excreted via the lungs. As a result long term
foreign deposition issues are hypothesized to not a problem. In addition, CaCO3, is tightly
controlled in the body to a certain pH, in this case 7.4.4 This is particularly ideal, as the
extracellular acidity induced by Warburg metabolism results in an extracellular pH between 6.4
to 7.2.5,6 As a result, CaCO3 dissolves selectively in these acidic regions resulting in both the
delivery of any cargo, and the neutralization of the pH towards more physiological range. These
pH changes alone have been shown to inhibit cancer growth, putatively due to changes in
enzyme kinetics, and are promising for synergy with other therapies, including chemotherapy,
radiation therapy, and immunotherapy. 7-18
For synergy to be possible, understanding the biodistribution and toxicity of CaCO3
nanoparticles is critical. However, unlike more standard gold and silver nanoparticles, nanoCaCO3 does not have significantly different intrinsic contrast to normal tissue due to the high
prevalence of calcium and carbonate in the body. As a result, nano-CaCO3 has not been imaged
in vivo. Imaging and/ or quantification of amount is critical to understand both timing and extent
of distribution of the particle for CaCO3 to be a useful platform.
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There are several challenges towards imaging nano-CaCO3 in vivo. TEM imaging of CaCO3
are hard to visualize due to equivalent electron density surrounding globules. Calcium and
carbonate measurements themselves are difficult to differentiate from the background
concentrations of calcium and carbonate. Because the particles dissolve in vivo, surface
modification with fluorescent or other contrast agents is not reliable.
Among imaging systems then, MR has the widest clinical translation possibility as MR allows
full depth penetration and time course imaging. MR has been used in the past to follow
magnetite nanoparticle distributions.19,20 In order to image nano-CaCO3 we undertook the
synthesis of a magnetite impregnated CaCO3 nanocrystal of similar properties to nano-CaCO3.
MR imaging of vaterite-magnetite allows for biodistribution testing of nano-CaCO3 both in
animal models, and in the future, in humans. The results of this study allow for the use of nanoCaCO3 as an organic biodegradable alternative to metal and polymeric nanoparticles for
nanotechnology in cancer therapy.
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5.2 Materials and Methods
5.2.1 Transmission Electron Microscope (TEM).
TEM micrographs were obtained using a FEI Spirit TEM (Hillsboro, USA) operated at 120 kV.
A 400-mesh Formvar® carbon-coated copper grid was glow-discharged in a vacuum evaporator
(Denton, Moorestown, New Jersey) for 30 s. The sample was prepared by placing 2 μL of
sonicated CaCO3 nanoparticles solution onto the grid and wicking off the excess sample with filter
paper after 30 s. Alternatively, for EtOH or DMSO solvent based solutions, 3 𝝁L of particle
solution were placed on the grid and left to dry out at room temperature or with the aid of a heat
gun.

5.2.2 X-Ray Diffraction (XRD).
XRD patterns were obtained by using the Bruker d8 Advance X-ray Diffractometer (Bruker,
USA) configured with a Cu X-Ray tube with 1.5418 Å for analysis of powder samples using
LYNXEYE_XE detector. For the analysis, fine acetone ground CaCO3 nanoparticles were kept
on a Zero Diffraction Plate (MTI Corporation, USA). XRD data were scanned from 20-60
degrees, with a 0.04 degree step size, a 0.5 s per step count time, with sample rotation turned on
(15 rotations per min), with a coupled two-theta/theta scan. The Bruker Diffrac.Eva program was
used for the evaluation and processing of X-ray diffraction scan data. Search-match operations
included search by DI list, by name, using chemistry filters, and creating an International Centre
for Diffraction Data (ICCDD PDF) database filter.

5.2.3 Hydrodynamic diameter and electro-kinetic zeta potential.
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To study agglomeration kinetics of CaCO3 nanoparticles, hydrodynamic diameter (Dh) was
measured using DLS (Malvern Instruments, Southborough, Massachusetts). Agglomeration
kinetics were measured on the basis of data obtained from TR-DLS.
The zeta potential was measured using a Malvern Zetasizer Nano ZS instrument. An applied
voltage of 100 V was used for the nanoparticles. A minimum of three measurements were made
per sample.

5.2.4 Determination of toxicity in rats
3 month old Sprig Dawley rats (n=3) were injected with an allometrically dosed 25.4
mg/Kg (to match the dose originally given to mice) of 30 mg/mL 100 nm CaCO 3 particles
in 2% rat serum albumin PBS supplemented with CaCl 2 and MgCl2. For control, 3 month
old Sprig Dawley rats (n=3) were injected with a vector of 2% rat serum albumin PBS
supplemented with CaCl2 and MgCl2 at an equivalent volume dosage as in the treated
group.

5.2.5 Determination of toxicity in cells
HT1080 cells were grown to near confluency in a 96 well plate and incubated with
CaCO3 at a decreasing concentration for 24 hours both under original IMDM media, and
IMDM media that was acidified to pH of 6.45 by titration with 1M HCl. Toxicity was
assessed via the sulfarhodamine B assay.

5.2.6 Imaging Test of Vaterite-magnetite nanocomposite
81 mg of Vaterite-magnetite was suspended in 1 mL of 2% BSA in PBS with MgCl2 and CaCl2
and then diluted five times, each time by a factor of 10. The resulting 1 mL solutions (81 mg/mL,
8 mg/mL, 0.8 mg/mL , 0.08 mg/mL, and 0.008 mg/mL ) were placed in eppendorf tubes and the
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transverse relaxation rate constant (R2) for each dilution was measured using a Car-PurcellMeiboom-Gill-type spin-echo sequence employing 12 echo times ranging from 13 to 300 ms and
a TR of 2 sec. The transverse relaxivity of the particle (r2) was calculated based on the linear
relation (assuming low concentrations of particles) between R2 and particle/iron concentration;
R2,obs = R2,0 + r2 [NP],
where R2,obs is a measured transverse relaxation rate constant, R2,0 is the calculated transverse
relaxation rate constant in the absence of the nanoparticle (often referred to as the "background"
R2), r2 is the transverse relaxivity of the particle, and [NP] is the nanoparticle concentration.

5.2.7 in vivo imaging
Three nude mice were injected with HT1080 tumors in the dorsal flank and grown to
approximately 1.5 cm x 1.5 cm. 1 mg of vaterite-magnetite was injected via tail vein and
measured using a Car-Purcell-Meiboom-Gill-type spin-echo sequence employing 12 echo times
ranging from 13 to 300 ms and a TR of 2 sec at T= post injection, ~1-3 hours, 4-6 hours, and 24
hours post injection.
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5.3 Results
5.3.1 Synthesis and characterization of vaterite-magnetite
The process of synthesizing the nano-composites is similar to the vaterite nanoparticle
synthesis process. Magnetite particles with a mean size of 15 nm (± 2.30 nm) were obtained
from Nano Research Facility of Washington University in St. Louis, USA and used for the
synthesis process. These magnetite particles were suspended in DI water and added to a
solution of hydrated calcium chloride. The remainder of the steps matched those we have
reported before for the vaterite particle synthesis. During the synthesis process the addition
of ethylene glycol to the solution was done to increase the viscosity of the solution and
thereby reduce the molecular diffusion21 giving particle sizes of 100 ± 8.5 nm. Thus, it is
seen that the viscosity of the solution plays a major role in the formation of the metastable
vaterite nanoparticles. Removal of water through washing is essential as the presence of
water encourages the particles to nucleate further and change phase from vaterite to calcite.
Fig. 5.1, presents the TEM images of the particles dispersed in methanol and it can be seen
that the vaterite particles have a characteristic spherical shape and size range of 100 ± 8.5
nm. Also, the images of the vaterite-magnetite nano-composites show dark spots matching
the size of the added magnetite nanoparticles within the bulk vaterite particle.
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500 𝜇m

20 nm

Fig. 5.1 TEM images of Vaterite-Magnetite particles when dispersed in methanol. (A)
Agglomerates of the vaterite-magnetite nano-composites. Inset in A: Scaled up image of the
vaterite-magnetite particles (scale bar of 20nm). The black dots indicated by arrows within the
bulk of the CaCO3 particle are the magnetite nanoparticles
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5.3.2 CaCO3 with magnetite incorporated remains vaterite.
To confirm the crystal phase of the CaCO3 or magnetite-CaCO3 nanoparticle, XRD patterns
were obtained by using the Bruker d8 Advance X-ray Diffractometer (Bruker, USA) configured
with a 1.5418 Å Cu X-Ray tube for analysis of powder samples using LYNXEYE_XE detector.
The diffraction pattern has clear represenation of vaterite phase of CaCO 3 as shown in Fig. 3.
However, there was a very small intensity peak of aragonite phase was also observed. Diffraction
pattern of magnetite-CaCO3 shows the consistancy in phase purity. (Figure 5.2)

Fig. 5.2 XRD Characterization of CaCO3 and magnetite-CaCO3 (m-CaCO3) composite
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5.3.3 Stability of CaCO3 in aqueous medium
A chemical compound used for biomedical application needs colloidal stability, help in storage,
transport and delivery of the compund into patient body. The synthesized particles may have huge
utility as pH neutralizers in cells22-24 due to their small size and high pH neutralization capacities.
To check their feasibility for pH neutralization in vivo, the size and stability of these particles in
different solvents is checked using Time-resolved dynamic light scattering technique (TR-DLS)
for duration of 30 minutes. The stability of both, the vaterite nanoparticles and the nanocomposites in a variety of solvents such as water, saline, Bovine serum albumin, Dulbecco’s
Modified Eagle Medium (DMEM), ethanol, methanol and Phosphate Buffer Saline (PBS). The
Fig. 5.3 shows the stability tests imply that albumin has a high affinity for the calcium
carbonate and resists two particles from coming together, thus stabilizing the particles in a
solution. The PBS solution encourages precipitation of the particles by increasing their
supersaturation.25 This leads to rapid precipitation encouraged by the addition of divalent
ions (Mg+2 or Ca+2) into the solution. The particles are also quite stable in DMEM which
indicates their possible applications in growing cell cultures requiring alkaline pH
environments. The results thus indicate that both the synthesized particles would be useful
for industrial applications in solvents such as ethanol and would be good for biomedical
applications by dissolving the same in a solution of albumin.
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A

Fig. 5.3 Stability test of vaterite nanoparticles in various solvents measured by TR-DLS. (A)
Vaterite-Magnetite nano-composites, the order of stability as 2% Albumin>Ethanol =
DMEM>Saline>PBS+MgCl2>Methanol>Water.

5.3.4 Imaging of nano-CaCO3 ex vivo and in vivo
Phantom tests demonstrate a sensitivity up to 0.1 mg/mL , a 100 fold dilution from
normal injection doses of 1 mg in 100 𝜇𝐿. Injection in vivo demonstrates a T2 drop (and a
1/T2 rise, first in the kidney, then liver, and finally tumor. This can be visualized in the T2
map as T2 drops post injection. We find that the particles cause a drop relatively rapidly,
with a trough at around 6 hours with almost complete return of signal by 24 hours. The
significant reduction of T2 in the bladder suggests a large renal clearance. (Figure 5.4)

129

Figure 5.4. MR Imaging of CaCO3. (a) Ex vivo phantom imaging of vaterite-magnetite at
different concentrations. (b) Change in 1/𝜏 over time in liver, kidney, and HT1080 tumor. (c)
Visualization of T2 changes with vaterite magnetite injection.

5.3.5 Toxicity Studies
For CaCO3 nanoparticles synthesized by this method to be a standard platform particle
for use in situations similar to more classical gold or metal based nanoparticles, a
biologically inert phenotype is necessary. Indeed, in cell studies we find that there is no
specific toxicity on HT1080 cells up to 1.20 mg/mL. In vivo, we tested this hypothesis using
a rat animal model for translational toxicity studies. Indeed, we find little to no significant
changes in organ weights, blood chemistries, and blood counts 24 hours after 25 mg/Kg
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CaCO3 injection compared to control (Figure 5.5). There was a significant albeit slight rise
in blood urea nitrogen, but because there was no concurrent creatinine or liver enzyme rise,
the rise was suggested to be nonspecific and may resolve with larger numbers of replicates
(Figure 5). There was nonspecific pathology across both control and treated groups that
was attributed to age. Given these results, we conclude that nano-CaCO3 is not inducing
widespread toxicity, and infer that this is most likely due to the pH not increasing beyond
7.4 in normal organs as reported before.
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Figure 5.5. CaCO3 is non-toxic (a) Toxicity of 100 nm CaCO3 particles in standard pH 7.4
IMDM media. (b) Toxicity of 100 nm CaCO3 particles in pH 6.45 IMDM media. (c) Organ
weights with vector versus 100 nm CaCO3. (d) Serum biomarker values (e) Complete blood
count. (f) Platelet count.
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5.4 Discussion
The ability to visualize CaCO3 in vivo allows for practical design of dosing and
pharmacokinetics. The ability to impregnate magnetite nanoparticles into the existing
nanoparticle formation is a significant improvement to answer this question. The magnetite in
particular is uniformly distributed across the particle, allowing for a better approximation of the
location of the entire particle.
However there are limitations with this model. Although magnetite allows for MR based
noninvasive imaging, it also has poor resolution and low sensitivity. As such, it is unclear exactly
when CaCO3 finishes clearing. It is also unclear whether the reduction in signal is due to
dissolution or washout of the particles.
Toxicity studies of the CaCO3 nanoparticles are important validation points for the
practical usage of CaCO3. Calcium and Carbonate are on their own easily degradable and
biocompatible. However, as a nanoparticle, the existence of liver and kidney toxicity remains a
concern. The results from the rat studies suggest minimal acute toxicity. Further studies on
chronic toxicity will be ideal.
Future studies on the material will look at other methods to validate biodistribution. Other
possibilities include Raman Microscopy and C13 mass spectrometry as methods to visualize the
intrinsic properties of the material, rather than using a co-carrier such as magnetite.
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Chapter 6: Systemic Administration of Nano-CaCO3
Inhibits Tumor Growth and Metastasis via Local pH
Increase
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6.1 Introduction
The current understanding of cancer development has evolved from a simple view of
uncontrolled growth stemming from gene mutation within a single cell to that of complex
interactions between different cell types and their local chemical environment. In particular,
the 4-5 fold increase in the extracellular hydrogen ion concentration around tumor cells,
previously considered a byproduct of upregulated glycolysis, appears to support elevated
tumor growth, immune evasion, and metastasis. 1-5 To combat these effects, various cancer
therapies focusing on modulating extracellular pH (pHe) of tumors have been investigated. 6
For instance, intracellular modulators of intrinsic proton transport and production such as
proton pump and carbonic anhydrase IX inhibitors have inhibited tumor growth by
increasing pH in vivo.1,6,7 However, the intracellular targets of these drugs are expressed in
non-cancerous cells and therefore can have off-target toxic effects.7 In addition, redundancy
of intracellular pathways can lead to drug resistance and loss of therapeutic efficacy over
time.8,9
To avoid intracellular resistance pathways, dietary alterations including sodium
bicarbonate can raise the systemic extracellular pH.2 Although a positive response has been
observed in some tumors, this approach requires the administration of large amounts of the
salt, does not target the tumors directly, has a transient effect on tumor pHe because of the
rapid clearance from circulation, and is expected to induce metabolic alkalosis, and
consequent morbidity.10
An alternative approach to directly modulate the acidic pHe of tumors is to develop
nanoparticle delivery vehicles with sustainable buffering capacity. This approach could
minimize the drug resistance potential seen in intracellular therapies, but also add the
140

selectivity seen with nanotechnology.11 Cationic secondary amine dendrimers have been
used to respond to acidic pH, particularly to escape the lysosome, for intracellular drug
delivery.12 However, dendrimers are capable of neutralizing only a small number of protons
(10-20 mole) per nanoparticle, thereby limiting their buffering capacity. Unless a nondesirable continuous infusion of the polyamine nanoparticles is used, their buffering
capacity is not regenerative and the products of amine protonation could induce off-target
toxicity. Inorganic nanoparticles, such as doped CaCO3, have been used for acid sensitive
drug release.13,14 However, rarely has any biocompatible inorganic nanoparticle been
intentionally designed and used to modulate tumor pHe.
In this work, we developed methods to prepare monodisperse nano-CaCO3 with size
ranges from 20 – 300 nm. We also identified a method to stabilize the materials in aqueous
media. Simulations and in vitro testing show that regenerative buffering capacity is
obtained because the products of this interaction, water and bicarbonate, dissociate from
the bulk nanoparticle core, creating a new surface to neutralize additional protons produced
by the cells. In addition, we demonstrate that nano-CaCO3 with distinct sizes can selectively
localize in the extracellular region of tumors and selectively modulate the pHe of tumors in
rodents, with the net effect of preventing or reducing tumor growth and metastasis (Figure
6.1).
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Figure 6.1. Schema of nano-CaCO3. (a) High dose CaCO3 enters via EPR and increases
pH to 7.4. Over time this continuous dose allows chronic maintenance of pH 7.4

6.2 Materials and Methods
6.2.1 Determination of pH change in acidic media versus normal media.
We determined CaCO3 dissolution over time by measuring pH changes in conditioned acidic
media and fetal bovine serum. Conditioned media was from a 7-day incubation of media with
HT1080 cells and an initial pH ~ 6.2. Final concentrations of CaCO3 in the cell free solutions were
controlled at 0.67 mg/mL. CaCO3 was added to conditioned media or serum in ~10 𝝁L of aqueous
vector (PBS + CaCl2 + MgCl2 + 2% bovine serum albumin) under hypoxic 5% CO2 conditions.
The pH was then measured after 1 hr.
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6.2.2 Determination of nano-CaCO3 dose-dependent pH changes in HT1080
cell culture medium.
HT1080 cells were plated at 105 cells/well in a 24 well plate overnight under hypoxic conditions
(0.3% O2 and 5% CO2), and then incubated with increasing amounts of 20 nm, 100 nm and 300
nm particles for 24 and 96 h. The particles were directly added and resuspended in media via
vortexing under hypoxic conditions (0.3% O2 and 5% CO2). The pH was measured after 24 and
96 h incubation. n = 3 for each sample.

6.2.3 Animal studies.
All animal studies were conducted in accordance with protocols approved by the Washington
University Animal Studies Committee. Mice were purchased from Charles River Laboratory.

6.2.4 Determination of pHe changes in vivo post bolus particle intravenous
injection.
HT1080 tumors were grown subcutaneously in dorsal flanks of athymic nude mice, in
dorsal bilateral flanks. Tumors generally grew in one flank. When the tumors growth
reaches approximately 50 mm3 or greater, the extracellular pH was measured using an
external pH electrode. Prior to these experiments, the mice had daily I.V. CaCO 3 (1 mg)
treatments for 3 weeks. Treatments were discontinued for at least 5 days before performing
the in vivo pH measurements. The average initial pH was 6.94 +/- 0.147.
The pH was measured using an extracellular pH electrode implanted into the tumor
following a 15 min equilibration period after electrode entry. The pH electrode was
calibrated within the week. About 1 mg of each size of particles (20 nm, 100 nm, 300 nm)
in a 100 𝝁L solution consisting of PBS, CaCl2, MgCl2 and 2% bovine serum albumin was
injected intravenously in individual mice. Approximately 100 𝝁L of aqueous vector (PBS,
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CaCl2, MgCl2, and 2% bovine serum albumin), 100 𝝁L of 0.84% sodium bicarbonate in
deionized (dI) water, and 100 𝝁L of 7.5% sodium bicarbonate in dI water were each serially
injected intravenously into the same mouse with 1 h gaps for measurement. Tumor sizes at
time of injection for this experiment were 12 mm x 9 mm (20 nm particles), 13.7 mm x
12.5 mm (100 nm), 13.5 mm x 15.5 mm (300 nm), 12.5 x 16.5 mm (.84% bicarbonate),
12.5 x 16.5 mm (7.5% bicarbonate), and 12.5 x 16.5 mm (vector). In general, the pH was
then followed each minute for a minimum of 1 h, or up to 3 h if any changes were seen.
Animals could tolerate this pH measurement procedure for approximately 4 h and exhibits
complete recovery after treatment. Bleeding, if any, was also noted.

6.2.5 Measurement of pH increases post multiple injections.
HT1080 tumors were grown subcutaneously in the dorsal bilateral flanks of athymic nude
mice. Typically, tumors grew in one flank. When grown to approximately 8.5 mm × 8.5
mm, extracellular pH was measured using an external pH electrode. The pH was measured
initially following a 15 min equilibration period post probe entry. About 100 𝝁L of 1 mg
particles (100 nm) in a solution of PBS, CaCl 2, MgCl2, and 2% albumin was injected I.V.
every hour for 3 h. The pH was measured continuously throughout.

6.2.6 Determination of tumor growth after CaCO3 administration.
HT1080 tumors were grown subcutaneously in the dorsal flanks of six athymic nude mice
(age ~ 8-10 weeks). After tumor growth reached about 100 mm3, I.V. treatment with nanoCaCO3 was initiated for three mice. About 1 mg of particles (100 nm) in 100 𝝁L of a
solution consisting of PBS, CaCl2, MgCl2, and 20 mg/mL of albumin was injected I.V.
every 24 h for 5 days in three mice. The tumor size was measured for each day concurrently
between treated and control for 12 days. The pH in the tumor region was then measured for
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each mouse as described above. During analysis, tumors that were considered too small to
measure but deemed palpable, were assigned the largest size measured on Day 1 (50 mm 3)
as a conservative estimate.

6.2.7 Determination of the effect of continuous infusion of CaCO3 on
tumor growth and metastasis.
4T1luc-GFP tumors were implanted into the mammary fat pads of Balb/c mice (syngeneic)
at 400,000 cells per mouse for 3 mice. On day 1 of implantation bioluminescence was used
to measure tumor size. 3 mg of nano CaCO3 was suspended into 200 𝝁𝑳 of EtOH along
with 100 𝝁M Cypate from a DMSO stock and placed in a Lynch coil connected to an Alzet
Osmotic Pump (Model 2004, DURECT Corporation, Cupertino, CA 95014) with a 28 day
infusion time (0.15 𝝁L/hr), and implanted on day 2. These pumps were implanted and
connected via jugular venous catheter into the animal. Animals were rested for 2-3 days.
On day 6, 1 mg of CaCO3 in 2%BSA+PBS+CaCl2 was injected IV, and the animals imaged
on day 6 post implantation, and then imaged approximately every 4 days by
bioluminescence. To detect lung metastasis, the primary tumor was obstructed by a black
covering and a long exposure taken on the chest region. 3 control mice were similarly
implanted with orthotopic mammary fat pad tumors and followed by bioluminescence
similarly for metastasis and the primary on day 1, 6, and every 4 days for up to 28 days.
These mice did not get an osmotic pump.

6.2.8 Determination of the effect of continuous infusion of CaCO3 on
tumor extravasation (metastasis mimicking model).
Pre IV injection of tumors 3 mg of nano CaCO3 was suspended into 200 𝝁𝑳 of EtOH along
with 100 𝝁M Cypate from a DMSO stock and placed in a Lynch coil connected to an Alzet
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Osmotic Pump (Model 2004, DURECT Corporation, Cupertino, CA 95014) with a 28 day
infusion time (0.15 𝝁L/hr), and implanted 3 days prior to tumor implant via jugular venous
catheter into the animals. These were implanted On the day of injection, 1 mg of CaCO3 in
2% BSA was injected via tail vein into each balb/c mouse. 3-5 minutes after 1 million
4T1luc GFP cells were injected by tail vein into the 3 balb/c mice. The mice were imaged
2 hours post implantation by bioluminescence, 2 days after, 6 days after, 10 days after and
16 days after before being sacrifice.
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6.3 Results
6.3.1 Efficacy of modulating the acidic pHe of tumors in vivo depends on
CaCO3 nanoparticle size
Predicated on the simulation studies, we assessed the buffering capacity of the
nanoparticles in cell-free media under 5% CO2 and hypoxic (0.3% O2) conditions (Figure
6.2a). In non-acidified conditioned media (pH 7.4), the solution pH was largely unchanged
in the presence of different sizes and concentrations of vaterite nano-CaCO3, as predicted
by simulations above. However, treatment of acidic conditioned media (pH 6.2) with any
of the particles (0.67 mg/mL) showed a rapid increase in pH, which did not exceed 7.2.
Similarly, the pH remained at about pH 7.2 after 24 h incubation of human fibrosarcoma
(HT1080) cells in normal cell culture conditions, irrespective of the nanoparticle doses used
(Figure 6.2b). At 96 h post HT1080 cellular induced acidification, nanoparticle sizedependent pH changes were observed, with the 20 nm materials having the highest increase
in pH. This could be attributable to the higher diffusion rate and the larger surface area of
the 20 nm nano-CaCO3.
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Fig. 6.2 Nano-CaCO3 increases pH up to 7.4 in vitro. (a), pH change in media at 5% CO2
shows a significant increase in pH when using particles as compared to vector alone. All
solutions were added in 10 𝜇L solvent (2% albumin + PBS with CaCl2 and MgCl2). (b), pH
change versus dose when incubated with HT1080 (human fibrosarcoma) cells using
different particle sizes shows an increase in pH with one dose of CaCO 3, as well as a
differential effect on pH at later time points of growth depending on size. Error bars refer
to the standard error across n = 3 biologic replicates.
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Despite recent advances in noninvasive methods to measure pH, they still suffer from
poor sensitivity to pHe and poor temporal resolution needed to measure the dynamic
changes in pH.15,16 To improve these parameters, we used an invasive pH electrode probe
for determining the in vivo pH (Figure 6.3a). I.V. administration of 1 mg bolus injections
of each of the 3 types of nano-CaCO3 in HT1080 tumor-bearing mice neutralized the pH
for over 3 h. The 100 nm nano-CaCO3 showed the highest 𝛥pH and longest effect (Figure
6.3b). The 20 nm particles appeared to diffuse into and out of the tumor area more rapidly
than the 100 nm particles.
Intuitively, larger particles are expected to exert higher response because of their
favorable EPR effect. However, the 300 nm nano-CaCO3 do not appear to appreciably
increase the pHe of tumors. The poor diffusion of these particles dictates that they can only
exert an effect in a small section of a three dimensional tumor environment. Our data also
show that flooding the mouse with a high concentration (0.3 - 0.4 g/Kg) of sodium
bicarbonate (~10x the nanoparticle I.V. dosage) did not induce a measurable pH change in
the tumor region (Figure 6.3b).
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Fig. 6.3 I.V. injections of nano-CaCO3 increase tumor pHe in vivo up to 7.4. (a) Image of
pH measurement setup. Probe is ~ 5 mm deep into the tumor, and ~5 mm wide, suggesting
that any pH value measured is most likely extracellular. (b) pH change in vivo with 1 mg
bolus intravenous injections (time point of injection symbolized on the graph as an injection
needle) of CaCO3 particles, bicarbonate, or vector. (c) pH change with multiple injections
of 100 nm particles in HT1080 tumor models demonstrate asymptotic changes near pH of
7.4.
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6.3.2 Transient neutralization of the acidic pHe can inhibit tumor growth
The effect of persistent neutralization of the acidic pHe of solid tumors is not known at this
time. Dynamic pH measurements in mice bearing HT1080 tumors indicate that 100 nm
sized nanoparticles administered at a bolus dose of 1 mg (0.04-0.05 g/kg body weight)
almost linearly increases the pH during the first 30 minutes, followed by a decrease at about
100 minutes. Repeated dosing at selected time points can maintain the pH close to 7.4
(Figure 6.3c), which matches the expectations of our simulation (Chapter 3).
Consistent with our hypothesis, we found that repeated daily administration of nanoCaCO3 significantly inhibited tumor growth (Figure 6.4a,b). Further, discontinuation of the
nano-CaCO3 treatment partially reversed this trend, resulting in the acceleration of tumor
growth rate (Figure 6.4c,d). This finding suggest the potential of tumor cell reprograming
in response to an initial assault by nano-CaCO3. Future studies will explore this concept.
Our results suggest that if a therapeutic outcome using this method is envisaged, multiple
doses of nano-CaCO3 may be required to sustain the neutralizing effect until either
depletion of the nanoparticles or reprogramming of the tumor cells in response to treatment.
To achieve a sustainable tumor-inhibitory effect, it will be necessary to optimize dosing,
combine nano-CaCO3 with other therapies, and improve targeting of the nano-CaCO3 to
tumors.
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Fig. 6.4 Repeated administration of 100 nm nano-CaCO3 inhibits tumor growth in vivo. (a),
Tumor size during treatment (first box) is significantly lower than control, which partially
equalizes after treatment ends (second box). (b), Controlling for initial size, the fold change
in tumor size is significantly reduced in treated tumors. (c), Growth rate of treated tumors
is decreased compared to control during treatments and only partially returns to normal
after treatment removal. (d), Removal of CaCO3 doubled the growth rate acceleration of
the tumor after treatment removal, with little change in control over the same time period.
Error bars represent standard error. Error bars refer to standard error with an n= 3 biologic
replicates for each arm.
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6.3.2 Persistent neutralization of pH via infusion of CaCO3 can inhibit
growth and metastasis.
CaCO3 infusion induces a persistent amount of CaCO3 buffer in the blood stream. Under
these conditions, we find metastasis is inhibited significantly via both the orthotopic and
IV infusion model. In particular we find that the orthotopic tumor is significantly inhibited
in growth. Based on the results of the IV infusion model, we note that the particles may
have some inhibition of the extravasation step. Based on the results of the orthotopic model
suggests that CaCO3 may have an effect on metastasis by both an effect on intravasation
and extravasation. (Figure 6.5)
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Fig. 6.5 Continuous CaCO3 infusion inhibits tumor growth and metastasis. (a) Tumor
metastasis can be seen in control versus lack therof in treatment mice in the orthotopic
4T1 model. (b) Orthotopic tumor growth in control versus treatment. (c) Reduction in
tumor extravasation in an IV model of metastasis under CaCO3 control vs treatment. (d)
Quantification of the reduction in lung bioluminescence immediately post injection of
4T1luc GFP tumor cells and 2 days later.
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6.4 Discussion
We have identified a facile, scalable method for mass production of sub-micron vaterite calcium
carbonate nanoparticles that are stable in biological media. Two different methods wherein
particle nucleation and cluster growth could be effectively controlled was demonstrated to obtain
the desired size ranges and crystal phases of calcium carbonate nanoparticles. (Chapter 4) For the
first time, we have demonstrated the capability of modulating the pH of solid tumors using nanoCaCO3. Efficient neutralization of the acidic pHe of tumors depends on particle size. Our results
suggest that large (> 300 nm) and small (< 20 nm) particles are less effective in neutralizing pHe
in vivo because of limited diffusion and transient retention in the tumor environment,
respectively. The ability of nano-CaCO3 to inhibit tumor growth and metastasis in vivo could
serve as a treatment paradigm for long-term tumor static therapy. Future studies will focus on
dose optimization, enhancement of tumor-targeting capability, determination of synergistic
treatments with complementary therapies, and assessment of potential tumor cell reprograming
following nano-CaCO3 treatment. A summary of all experiments in this chapter and above can
be seen in Table 6.1.
Table 6.1: Experimental plan to develop nano CaCO3 for modulating pH in tumors
Experiment

Objective/hypothesis

Techniques

Notes

Simulation of

To analyses pH transition with

MATLAB

Simulation of nano

CaCO3 dissolution

𝜇m resolution

CaCO3 dissolution

in vivo

in vivo
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Synthesis of

Synthesis of 20 nm, 100 nm and

Sol-gel

Morphological

CaCO3

300 nm

synthesis, gas

controlled

diffusion

nanoparticle

synthesis

synthesis

TEM, DLS

Fractal nature and

nanoparticles

Characterization

Morphology, zeta potential

of nanoparticles

hydrodynamic
diameter

Aqueous Solvent

Crystal nature

XRD

Vaterite

Stability of nanoparticles

TR-DLS,

Using different

TEM, XRD

vector system

pH probe

CaCO3 dissolution

Identification
In vitro cell free

Test the kinetics and dose

testing of nano-

response pH neutralization in cell

and pH changes in

CaCO3

free conditioned media and

conditioned media

serum
In vitro cell

Dose response on pH change

pH probe,

To verify the

incubation with

post incubation period with cells

HT1080 Cell

experimental results

culture

of cell free

particles

experiments with
cells
In vivo testing of

pH changes in vivo post bolus

HT1080

nano-CaCO3

particle IV injection

tumors,
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ncr/ncr nude

To verify pH

balb/c mice

modulating in model

pH increases post multiple

HT1080

injections

tumors,

organism

ncr/ncr nude
balb/c mice
Demonstrate decrease in tumor

HT1080

Tumor growth rate

growth from the increase in pHe

tumors,

is inhibited with

over time in immunodeficient

ncr/ncr nude

CaCO3 that partially

mice

balb/c mice

reverses with
removal

Demonstrate inhibition in tumor

4T1luc-GFP

Metastasis and

growth and metastasis from the

tumors, Balb/c

tumor growth is

increase in pHe over time in

mice

inhibited with

immunocompetent mice with

CaCO3 continuous

continuous infusion

infusion.

A shortcoming of our study is the difficulty in using an invasive method to determine in
vivo pHe, which could affect the accuracy of the pH measurement. Additionally, repeated
measurements requiring removal and replacement of the pH probe is cumbersome and
prone to error. These challenges could be addressed by developing a precise and accurate
noninvasive imaging approach to measure pH longitudinally.
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Chapter 7. Conclusions and Future Directions
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7.1 Conclusions
The extracellular pH of cancer remains a hallmark worth manipulating for cancer
treatment. Prior to this work, it had been difficult to modulate pH in tumors in a sustainable
fashion in vivo without significant side effects for long durations.1-7 In this thesis we describe the
importance of pH on the extracellular environment in cancer and demonstrate the development
of a nanomaterial method to modulate this pH in vivo. This new tool enables both providers and
researchers to practically tackle the question of extracellular pH modification. We discover that
the use of the novel nanomaterial (nano-CaCO3 ) does have a significant therapeutic effect on
both tumor growth and metastasis, at dosage levels of carbonate that are almost 8000x smaller
than by oral systemic dosing of aqueous sodium bicarbonate. 1,3 In the process, we present new
biological observations, diffusion and dissolution modeling of nanomaterials, novel material
synthesis methods, new MR contrast agents for bio distribution profiling, and the use of
nanomaterials in osmotic pumps for continuous administration.
The observation of OCT-4 expression under acidic stress in fibroblast stromal cells is
significant in that it demonstrates how the acidic pH generated by tumors has a functional effect
on its surroundings. The implications of this observation remain significant, including a potential
avenue to explain the recruitment of stromal cells to the tumor microenvironment. Perhaps
further interesting is how widespread the phenomenon appears, in multiple solid tumor types,
further emphasizing the ubiquity of pH and its downstream effects as a hallmark of cancer.
The mathematical modeling of CaCO3 dissolution in vivo is one of only a few studies
describing modeling of a nanomaterials. 8-11The subsequent studies validate the model’s
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prediction, primarily that CaCO3 despite having a pKa of 9, in vivo, retains a physiological pH
sensitivity to 7.4. It also implies significant things about the proposed biodistribution and pH
maintenance paradigms that influenced doping schedule. For instance, because there is a stable
point at 7.4, raising the pH itself to 7.4 may require substantial amounts of nanoparticle, but
maintaining the pH requires very little, only enough to remove any newly produced acid.
Importantly this also meant that under continuous infusion, the first bolus would be used
primarily to increase pH, with subsequent dosages only serving to increasing the buffering
capacity of the tissue. Continuous presence of a small amount CaCO3 nanoparticles thus is very
important to maintain this equilibrium. The pH dropping again would mean the entire process
has to start over. This fundamental prediction influences the usage of the continuous osmotic
pump and helps explains the significantly greater growth inhibition under continuous infusion
than daily bolus injections.
The synthesis of nano-CaCO3 required a new way to develop and stabilize nano-crystals.
Carbonate nano-crystals in particular are hard to make and grow because of their propensity to
fuse and become larger. Interestingly, in the process of development, we discover a vacuum
diffusion method where the size is actually a function of the ammonium bicarbonate
nanocrystals. This result means that we can make carbonate nanocrystals of a number of metals
as shown by the formation of AuCO3, FeCO3, and ZnCO3.
An important component of making pH modulation a practical therapeutic modality was
toxicity and biodistribution. Via this section, we demonstrate the production, characterization
and imaging of CaCO3-magnetite which identified CaCO3 as undergoing an approximately 24
hour clearance pattern. Toxicity studies with rats also demonstrate the safety of CaCO3
suggesting further its capability to be a practical therapeutic modality.
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Further studies then looking a pH increases demonstrate how CaCO3 injection induces a
localized increase in pH at the tumor site that only goes up to 7.4. The therapeutic implications
are seen both in a serial injection model of a fibrosarcoma, and a continuous infusion model of
syngeneic breast cancer model. We see both growth inhibition and importantly metastasis
inhibition. This effect validates what was seen during systemic administration of base albeit
without the toxic side effects of metabolic alkalosis.
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7.2 Future Work
Further work remains to be done to continue the story and make the therapeutic
modulation of pH a viable therapeutic modality in the clinic. These studies can be roughly
divided into explorations of biology and biological effects, as well as advances in the material
science.
Focusing on the biology, further studies will explore whether the nano-CaCO3 induced
pH increase causes downstream biological effects on both the tumor and surrounding stroma,
including OCT-4 expression observed as being caused by extracellular acidity. With this tool,
many of the earlier in vitro studies on pH can be validated in vivo. Identification of changes in
protein expression and RNA/DNA expression of both the stroma and tumor cells will guide
subsequent therapeutic questions. The synergy with other therapies is an entirely separate field of
study that will be exciting to dive into. Already, we know that several chemotherapies have
significant susceptibility to extracellular pH. Increasing pH may synergistically increase those
chemotherapies effectiveness.
Focusing on the materials science, further work is needed on methodology for scaling the
materials, develop of an appropriate pump to distribute longer than 1 month. A larger pump for
larger animals will be needed to demonstrate benefit. Alternative delivery methods, including
peritoneal administration, remains possible and unexplored. Nano-CaCO3 remains unadorned.
Although this is valuable for systemic nonspecific administration, this means further work is
necessary to add a targeting capability to the particle, including adding a coating, and/or a
targeting group, potentially increasing the retention of nano-CaCO3. The development of other
carbonates such as gold carbonate, zinc carbonate, and iron carbonate, may have utility on both
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the extracellular pH in cancer, but also applications throughout the sciences. Further work is
necessary to characterize these other carbonate nanocrystals for their properties.
Excitingly, nano-CaCO3 lays a foundation for significant headway into a number of
biological questions regarding modifying pH in cancer, and advancing the field of material
science for nanocrystal design and engineering. Perhaps most importantly, nano-CaCO3 enables
the practical application of a novel therapeutic modality: increasing the extracellular pH in
cancer.
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